|
|
Zymeworks Inc (NASDAQ: ZYME) |
|
Overall company Market Share Q1 2025 |
*Market share is calculated based on total revenue.
News about Zymeworks Inc Contracts |
May 22, 2025
Paving the Path in Oncology: Zymeworks Sets the Stage for Medical Breakthroughs at Premier Global Conferences In an inspiring move set to influence the oncology landscape significantly, Zymeworks Inc. (Nasdaq: ZYME) is gearing up to highlight its innovative strides in cancer treatment at the most anticipated global medical conferences of the year. Headquartered in Vancouver, British Columbia, this clinical-stage biotechnology company is poised to showcase a commanding array of presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Society of Medical Oncology (ESMO) Gynaecological Cancers Congress. This marks a pivotal moment for Zymeworks as it continues to unveil ...
|
November 5, 2024
Zymeworks Inc. a leading biotechnology firm focused on innovative biotherapeutics, has recently made significant strides in the development of ZW191, a novel folate receptor (FR)-targeted topoisomerase I inhibitor antibody-drug conjugate (ADC). With the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA), ZW191 is poised to enter clinical evaluation, targeting advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers (NSCLC). This article discusses the implications of ZW191 in cancer therapy, highlights the ongoing Phase 1 clinical trial, and summarizes the preclinical advancements presented at the American Association for C...
|
August 22, 2024
Zymeworks Inc. Poised for Strategic Engagement at Prominent Investor Conferences Vancouver, British Columbia, August 22, 2024 - Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company at the frontier of developing innovative, multifunctional biotherapeutics, today disclosed its planned participation in a series of high-profile investor conferences. This engagement aligns with Zymeworks? commitment to advancing the standard of care for challenging and intractable diseases through its diverse therapeutic pipeline.Zymeworks robust portfolio features cutting-edge biotherapeutics designed to address myriad complex diseases for which treatment options remain limited or ineffective. The company?s s...
|
Publicly Traded Peers of Zymeworks Inc
Cardiff Oncology Inc
Share Performance
+4.12%
Over The Past 5 Days
|
Cardiff Oncology Inc
Profile
Cardiff Oncology Inc. is a biomedical company that follows a business model focused on developing and commercializing transformative therapies for the treatment of cancer. They leverage cutting-edge research and technologies to discover novel drug candidates and conduct pre-clinical and clinical trials to evaluate their efficacy. Through strategic partnerships and collaborations, they aim to bring their innovative oncology treatments to market, addressing unmet medical needs and improving patient outcomes.
More about Cardiff Oncology Inc 's Market Share
|
Blueprint Medicines Corporation
Share Performance
+10.03%
This Quarter
|
Blueprint Medicines Corporation
Profile
The business model of Blueprint Medicines Corporation revolves around the development and commercialization of precision therapies for patients with genomically defined cancers and rare diseases. They actively pursue a strategy of genomically targeted drug discovery and development, utilizing advanced technologies and clinical expertise to bring potentially life-changing treatments to market. The company focuses on creating value through strategic collaborations, licensing agreements, and the commercialization of their innovative therapies.
More about Blueprint Medicines Corporation's Market Share
|
Affimed N v
Share Performance
+35.45%
Over The Past 5 Days
|
Affimed N v
Profile
Affimed N is a biopharmaceutical company that operates through a partnership-based business model, collaborating with leaders in the healthcare industry and utilizing its proprietary technology platform to develop novel cancer immunotherapies. By leveraging these collaborations and its innovative platform, Affimed N aims to advance the development of effective treatments for cancer.
More about Affimed N v 's Market Share
|
89bio Inc
Share Performance
+37.54%
30 Days
|
89bio Inc
Profile
89bio Inc operates as a biopharmaceutical company focused on developing and commercializing transformative therapies for liver and cardio-metabolic diseases. The company's business model revolves around identifying and developing potential drug candidates through its unique platform, with the aim of meeting the unmet medical needs of patients. By leveraging its expertise and scientific advancements, 89bio Inc strives to bring innovative treatments to market, improving the lives of individuals suffering from these conditions.
More about 89bio Inc 's Market Share
|
Inhibrx Biosciences Inc
Share Performance
+3.13%
Over The Past 5 Days
|
Inhibrx Biosciences Inc
Profile
Inhibrx Inc operates using a business model that focuses on the development and commercialization of therapeutics. The company leverages its innovative technology platform to create a diverse pipeline of biologics for the treatment of various diseases. Inhibrx Inc aims to collaborate with strategic partners to advance the development of its pipeline and expand its reach in the healthcare market.
More about Inhibrx Biosciences Inc 's Market Share
|
Satsuma Pharmaceuticals Inc
Share Performance
+27.63%
This Year
|
Satsuma Pharmaceuticals Inc
Profile
Satsuma Pharmaceuticals Inc's business model focuses on the development and commercialization of therapeutics for the treatment of migraine.
More about Satsuma Pharmaceuticals Inc 's Market Share
|
Effector Therapeutics Inc
Share Performance
-99.89%
One Year
|
Effector Therapeutics Inc
Profile
Effector Therapeutics Inc is a biotech company focused on developing and commercializing effective cancer treatments.
More about Effector Therapeutics Inc 's Market Share
|
Macrogenics Inc
Share Performance
-15.64%
30 Days
|
Macrogenics Inc
Profile
Macrogenics Inc is a biopharmaceutical company that focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer and autoimmune diseases.
More about Macrogenics Inc 's Market Share
|
Heron Therapeutics Inc
Share Performance
-46.22%
One Year
|
Heron Therapeutics Inc
Profile
Heron Therapeutics Inc is a biotechnology company that focuses on developing innovative treatments for patients suffering from pain and other serious conditions. Their business model revolves around researching, developing, and commercializing novel therapeutics utilizing their proprietary technology platforms. By collaborating with healthcare providers and other industry partners, Heron Therapeutics aims to bring effective and safe solutions to patients in need.
More about Heron Therapeutics Inc 's Market Share
|
Theseus Pharmaceuticals Inc
Share Performance
+0.74%
30 Days
|
Theseus Pharmaceuticals Inc
Profile
Theseus Pharmaceuticals Inc operates on a business model focused on the development and commercialization of pharmaceutical products.
More about Theseus Pharmaceuticals Inc 's Market Share
|
Syndax Pharmaceuticals Inc
Share Performance
-25.94%
30 Days
|
Syndax Pharmaceuticals Inc
Profile
Syndax Pharmaceuticals Inc has a business model centered around developing innovative cancer treatments. They focus on leveraging their expertise in epigenetics and immuno-oncology to create therapies that target specific cancer types. Syndax collaborates with strategic partners and utilizes clinical trials to bring their treatments to market and improve patient outcomes.
More about Syndax Pharmaceuticals Inc 's Market Share
|
Inmed Pharmaceuticals Inc
Share Performance
0.00%
Over The Past 5 Days
|
Inmed Pharmaceuticals Inc
Profile
Inmed Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of cannabinoid-based therapies for various diseases. The company's business model revolves around conducting research and development to identify novel drug candidates, conducting pre-clinical and clinical trials to test the safety and efficacy of these candidates, and seeking partnerships or collaborations with other pharmaceutical companies for the further development and commercialization of successful therapies. By leveraging advancements in cannabinoid science, Inmed Pharmaceuticals aims to provide innovative medical treatments for unmet medical needs.
More about Inmed Pharmaceuticals Inc's Market Share
|
Optinose Inc
Share Performance
+43.28%
This Year
|
Optinose Inc
Profile
Optinose Inc is a pharmaceutical company that specializes in developing and commercializing innovative therapies delivered through its proprietary device called Optinose Exhalation Delivery System. They generate revenue by licensing and selling their treatment products for conditions like nasal polyps and migraines.
More about Optinose Inc 's Market Share
|
Iteos Therapeutics Inc
Share Performance
+14.75%
30 Days
|
Iteos Therapeutics Inc
Profile
Iteos Therapeutics Inc is a company that focuses on developing innovative immunotherapies to treat cancer by targeting the tumor microenvironment.
More about Iteos Therapeutics Inc 's Market Share
|
Geron Corp
Share Performance
-59.72%
This Year
|
Geron Corp
Profile
Geron Corp is a biopharmaceutical company that focuses on the discovery and development of therapeutic products for the treatment of cancer and chronic degenerative diseases. Their business model is based on researching and identifying innovative drug candidates, conducting preclinical and clinical trials to evaluate their safety and efficacy, and ultimately partnering with larger pharmaceutical companies for late-stage clinical development and commercialization. Geron Corp aims to leverage their scientific expertise and strategic collaborations to bring novel therapies to market and improve patient outcomes.
More about Geron Corp's Market Share
|
Ikena Oncology Inc
Share Performance
-30.91%
This Year
|
Ikena Oncology Inc
Profile
Ikena Oncology Inc's business model focuses on developing innovative cancer therapies through targeted drug discovery and development.
More about Ikena Oncology Inc 's Market Share
|
Milestone Pharmaceuticals inc
Share Performance
+19.38%
Over The Past 5 Days
|
Milestone Pharmaceuticals inc
Profile
Milestone Pharmaceuticals Inc. is a pharmaceutical company that focuses on developing and commercializing innovative therapies for cardiovascular diseases. Their business model revolves around identifying unmet medical needs in the cardiovascular space and leveraging their expertise in drug development to create novel treatments. By conducting rigorous research, clinical trials, and collaborations, Milestone Pharmaceuticals aims to bring effective and safe medications to market, positively impacting patients' lives.
More about Milestone Pharmaceuticals inc 's Market Share
|
Monte Rosa Therapeutics Inc
Share Performance
-3.41%
Over The Past 5 Days
|
Monte Rosa Therapeutics Inc
Profile
Monte Rosa Therapeutics Inc operates under a specific business model that focuses on a unique approach in the field of therapeutics.
More about Monte Rosa Therapeutics Inc 's Market Share
|
Oncorus Inc
Share Performance
+401.99%
This Quarter
|
Oncorus Inc
Profile
Oncorus Inc is a biotechnology company that specializes in developing next-generation viral immunotherapies to treat various types of cancers. Their business model revolves around leveraging the power of oncolytic viruses, which selectively target and destroy cancer cells while stimulating an immune response against the tumor. Oncorus focuses on rigorous research, clinical development, and potential partnerships to advance their innovative therapies towards commercialization and widespread patient access.
More about Oncorus Inc 's Market Share
|
Redhill Biopharma Ltd
Share Performance
-84.10%
One Year
|
Redhill Biopharma Ltd
Profile
Redhill Biopharma Ltd is a specialty pharmaceutical company focused on improving patient care and developing innovative treatments. Their business model revolves around advancing the research and development of drug candidates in therapeutic areas with unmet medical needs. By seeking partnerships and leveraging their in-house expertise, they aim to bring these potential treatments to market for the benefit of patients worldwide.
More about Redhill Biopharma Ltd 's Market Share
|
Salarius Pharmaceuticals inc
Share Performance
-42.50%
This Quarter
|
Salarius Pharmaceuticals inc
Profile
Salarius Pharmaceuticals Inc's business model revolves around the development and commercialization of innovative treatments for rare and aggressive cancers.
More about Salarius Pharmaceuticals inc 's Market Share
|
Oramed Pharmaceuticals Inc
Share Performance
-9.40%
One Year
|
Oramed Pharmaceuticals Inc
Profile
Oramed Pharmaceuticals Inc. is a biopharmaceutical company with a business model focused on developing innovative oral drug delivery solutions.
More about Oramed Pharmaceuticals Inc's Market Share
|
Nextcure Inc
Share Performance
-38.07%
This Year
|
Nextcure Inc
Profile
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
More about Nextcure Inc 's Market Share
|
Sellas Life Sciences Group Inc
Share Performance
+76.64%
This Year
|
Sellas Life Sciences Group Inc
Profile
Sellas Life Sciences Group Inc is a biopharmaceutical company that focuses on developing and commercializing immunotherapeutic products for various cancer indications, utilizing innovative technologies. The company aims to meet the need for more effective treatment options by leveraging its expertise in immuno-oncology and precision medicine.
More about Sellas Life Sciences Group Inc 's Market Share
|
Autolus Therapeutics Plc
Share Performance
-21.03%
This Quarter
|
Autolus Therapeutics Plc
Profile
Autolus Therapeutics Plc is a biopharmaceutical company that focuses on the development and commercialization of next-generation engineered T-cell therapies for the treatment of cancer. Their business model is centered around utilizing innovative technology and expertise to create and advance novel therapies aimed at improving patient outcomes in oncology.
More about Autolus Therapeutics Plc's Market Share
|
Pmv Pharmaceuticals Inc
Share Performance
-16.11%
30 Days
|
Pmv Pharmaceuticals Inc
Profile
Pmv Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing precision therapies for cancer patients. They employ a collaborative business model that combines deep scientific expertise, strategic partnerships, and advanced technology to identify and target specific genetic alterations in cancer cells. By leveraging these insights, Pmv Pharmaceuticals aims to create innovative treatments that can improve patient outcomes and address unmet medical needs in oncology.
More about Pmv Pharmaceuticals Inc 's Market Share
|
Ensysce Biosciences Inc
Share Performance
-74.27%
One Year
|
Ensysce Biosciences Inc
Profile
Ensysce Biosciences Inc is a biopharmaceutical company that operates on a business model centered around developing and commercializing novel therapies using their proprietary drug delivery technology, known as MedXPRESS?. This technology allows for precise control of drug release and enhanced delivery to target tissues, with a focus on improving therapeutic outcomes and patient compliance.
More about Ensysce Biosciences Inc 's Market Share
|
Bolt Biotherapeutics Inc
Share Performance
-59.24%
One Year
|
Bolt Biotherapeutics Inc
Profile
Bolt Biotherapeutics Inc's business model focuses on developing novel immunotherapies for the treatment of cancer.
More about Bolt Biotherapeutics Inc 's Market Share
|
Cns Pharmaceuticals Inc
Share Performance
-14.73%
Over The Past 5 Days
|
Cns Pharmaceuticals Inc
Profile
CNS Pharmaceuticals Inc's business model focuses on developing innovative solutions and treatments for central nervous system diseases.
More about Cns Pharmaceuticals Inc 's Market Share
|
Phenomex Inc
Share Performance
+0.58%
Over The Past 5 Days
|
Phenomex Inc
Profile
Phenomex Inc operates as a technology company specializing in the development and commercialization of cutting-edge solutions in various industries. Their business model focuses on leveraging their expertise to create innovative products and services, catering to market needs and generating revenue through sales and licensing agreements.
More about Phenomex Inc 's Market Share
|
Evoke Pharma Inc
Share Performance
-27.47%
One Year
|
Evoke Pharma Inc
Profile
Evoke Pharma Inc operates as a specialty pharmaceutical company focusing on the development and commercialization of drugs for the treatment of gastrointestinal disorders. Their business model involves researching, developing, and marketing innovative pharmaceutical products to address unmet medical needs in the gastrointestinal market.
More about Evoke Pharma Inc 's Market Share
|
Soligenix inc
Share Performance
-25.51%
This Quarter
|
Soligenix inc
Profile
Soligenix Inc. is a biopharmaceutical company that focuses on developing and commercializing products to treat rare diseases. Their business model revolves around leveraging their expertise in developing innovative therapies and securing partnerships and collaborations with academic institutions, government agencies, and other companies to accelerate the development process. Soligenix also strategically seeks funding through grants and licensing deals to support their pipeline and growth initiatives.
More about Soligenix inc 's Market Share
|
Phio Pharmaceuticals Corp
Share Performance
-7.89%
This Year
|
Phio Pharmaceuticals Corp
Profile
Phio Pharmaceuticals Corp's business model revolves around developing and commercializing innovative RNA-based therapeutics to treat various diseases and improve patient outcomes.
More about Phio Pharmaceuticals Corp 's Market Share
|
Moleculin Biotech Inc
Share Performance
-80.71%
One Year
|
Moleculin Biotech Inc
Profile
Moleculin Biotech Inc is a biopharmaceutical company that develops innovative cancer therapies by targeting key enzymes and signaling pathways involved in the progression of tumors. Their business model revolves around conducting preclinical and clinical trials to advance their drug candidates, with a focus on maximizing therapeutic impact and commercial potential.
More about Moleculin Biotech Inc 's Market Share
|
Monopar Therapeutics Inc
Share Performance
-11.93%
This Quarter
|
Monopar Therapeutics Inc
Profile
Monopar Therapeutics Inc operates under a business model focused on developing and commercializing innovative therapeutics for the treatment of various cancers. The company aims to leverage strategic partnerships with academic institutions and other pharmaceutical companies to facilitate the development and distribution of their products.
More about Monopar Therapeutics Inc 's Market Share
|
Kazia Therapeutics Limited
Share Performance
-74.36%
One Year
|
Kazia Therapeutics Limited
Profile
Kazia Therapeutics Limited is a biotechnology company that focuses on developing and commercializing innovative oncology therapies. Their business model revolves around advancing novel drug candidates, conducting clinical trials, and collaborating with partners to bring their products to market.
More about Kazia Therapeutics Limited's Market Share
|
Tyme Technologies Inc.
Share Performance
+26.87%
Over The Past 5 Days
|
Tyme Technologies Inc.
Profile
Tyme Technologies Inc. is a biotechnology company that operates through the development and commercialization of pharmaceutical products. Their business model focuses on the research, development, and sale of proprietary cancer therapy drug candidates. By leveraging innovative technology and strategic partnerships, Tyme aims to bring novel treatment options to the market, improving patient outcomes and addressing unmet medical needs in the oncology field.
More about Tyme Technologies Inc.'s Market Share
|
Genprex Inc
Share Performance
+3.19%
30 Days
|
Genprex Inc
Profile
Genprex Inc's business model focuses on the development and commercialization of gene therapies for the treatment of cancer.
More about Genprex Inc 's Market Share
|
Bellicum Pharmaceuticals Inc
Share Performance
0.00%
This Year
|
Bellicum Pharmaceuticals Inc
Profile
Bellicum Pharmaceuticals Inc's business model is focused on the development and commercialization of innovative cellular immunotherapies for the treatment of cancers and other serious diseases.
More about Bellicum Pharmaceuticals Inc 's Market Share
|
Provectus Biopharmaceuticals Inc
Share Performance
+10.10%
Over The Past 5 Days
|
Provectus Biopharmaceuticals Inc
Profile
Provectus Biopharmaceuticals Inc's business model involves the development and commercialization of innovative therapies in the biopharmaceutical industry.
More about Provectus Biopharmaceuticals Inc 's Market Share
|
Peak Pharmaceuticals Inc
Share Performance
-36.03%
This Year
|
Peak Pharmaceuticals Inc
Profile
Peak Pharmaceuticals Inc's business model involves the development, manufacturing, and distribution of pharmaceutical products.
More about Peak Pharmaceuticals Inc 's Market Share
|
Bellerophon Therapeutics inc
Share Performance
-1.64%
Over The Past 5 Days
|
Bellerophon Therapeutics inc
Profile
Bellerophon Therapeutics Inc operates under a business model focused on developing and commercializing innovative therapies for cardiopulmonary diseases. They aim to leverage their unique technology platform to advance their product pipeline, ultimately improving patient outcomes and driving sustainable growth in the healthcare market.
More about Bellerophon Therapeutics inc's Market Share
|
Propanc Biopharma Inc
Share Performance
0.00%
This Quarter
|
Propanc Biopharma Inc
Profile
Propanc Biopharma Inc's business model involves developing and commercializing novel therapeutics for the treatment of pancreatic and colorectal cancer.
More about Propanc Biopharma Inc 's Market Share
|
Inhibitor Therapeutics Inc
Share Performance
0.00%
One Year
|
Inhibitor Therapeutics Inc
Profile
Inhibitor Therapeutics Inc's business model focuses on developing and commercializing innovative inhibitors for targeted therapies.
More about Inhibitor Therapeutics Inc 's Market Share
|
Rayzebio Inc
Share Performance
+175.04%
This Quarter
|
Rayzebio Inc
Profile
Rayzebio Inc is a biotechnology company that operates on a business model focused on developing innovative cancer therapies by leveraging cutting-edge technologies and advanced research methods. They aim to identify and target key biological pathways to provide personalized treatment options for patients, ultimately improving cancer outcomes.
More about Rayzebio Inc 's Market Share
|
Sagimet Biosciences inc
Share Performance
+10.58%
30 Days
|
Sagimet Biosciences inc
Profile
Sagimet Biosciences Inc is a biopharmaceutical company that operates on a research-based business model focused on developing therapeutic solutions for metabolic diseases. They employ a multidisciplinary approach that combines scientific research, preclinical assessments, and clinical trials to advance their drug candidates. Sagimet Biosciences aims to bring effective treatments to patients by leveraging their expertise in metabolic disease biology and collaborating with key stakeholders in the medical community.
More about Sagimet Biosciences inc 's Market Share
|
Mira Pharmaceuticals Inc
Share Performance
-7.58%
Over The Past 5 Days
|
Mira Pharmaceuticals Inc
Profile
Mira Pharmaceuticals Inc's business model is focused on the development and sale of pharmaceutical products, with a particular emphasis on research and innovation in the healthcare industry.
More about Mira Pharmaceuticals Inc 's Market Share
|
Cabaletta Bio Inc
Share Performance
-24.89%
This Year
|
Cabaletta Bio Inc
Profile
Cabaletta Bio Inc's business model revolves around developing and commercializing genetically engineered T cell therapies for the treatment of autoimmune diseases. They aim to utilize their proprietary technology platform to engineer Chimeric AutoAntibody Receptor (CAAR) T cells, which are designed to selectively target and eliminate disease-causing B cells. By focusing on autoimmune diseases with high unmet medical needs, Cabaletta Bio Inc aims to provide effective and personalized therapeutic solutions to patients.
More about Cabaletta Bio Inc 's Market Share
|
Relay Therapeutics Inc
Share Performance
-0.68%
Over The Past 5 Days
|
Relay Therapeutics Inc
Profile
Relay Therapeutics Inc is a biotechnology company focused on developing targeted therapies for diseases by leveraging insights from protein motion. Their business model involves utilizing computational simulations and algorithms to discover and design small molecule therapies that can effectively target specific proteins involved in various diseases.
More about Relay Therapeutics Inc 's Market Share
|
Aura Biosciences Inc
Share Performance
-21.57%
This Quarter
|
Aura Biosciences Inc
Profile
Aura Biosciences Inc is a biotechnology company that focuses on developing and commercializing therapies to treat cancer. They utilize their proprietary Tumor Paint technology to selectively deliver light-activated drugs directly to tumors, aiming to improve treatment outcomes and minimize side effects.
More about Aura Biosciences Inc 's Market Share
|
C4 Therapeutics Inc
Share Performance
-54.15%
This Quarter
|
C4 Therapeutics Inc
Profile
C4 Therapeutics Inc operates on a business model that focuses on developing novel therapies using their proprietary Degronimid? platform, designed to selectively target and degrade disease-causing proteins. This approach potentially offers a new avenue for treating various diseases by harnessing the body's natural protein degradation machinery.
More about C4 Therapeutics Inc 's Market Share
|
Bioatla Inc
Share Performance
-14.53%
30 Days
|
Bioatla Inc
Profile
Bioatla Inc's business model focuses on developing and commercializing innovative antibody-based therapeutics to treat various diseases.
More about Bioatla Inc 's Market Share
|
Vor Biopharma Inc
Share Performance
-75.72%
30 Days
|
Vor Biopharma Inc
Profile
Vor Biopharma Inc's business model focuses on developing novel cell therapies for the treatment of cancer.
More about Vor Biopharma Inc 's Market Share
|
Hst Global Inc
Share Performance
0.00%
30 Days
|
Hst Global Inc
Profile
HST Global Inc is a diversified company that operates through its subsidiaries in various sectors, including telecommunications, health and wellness, and alternative energy. Their business model focuses on acquiring and developing innovative technologies and solutions to provide sustainable and efficient services in these industries.
More about Hst Global Inc 's Market Share
|
Mink Therapeutics Inc
Share Performance
+639.51%
One Year
|
Mink Therapeutics Inc
Profile
Mink Therapeutics Inc is a biotechnology company that focuses on developing mRNA therapeutics for treating genetic diseases. Their business model primarily revolves around utilizing messenger RNA (mRNA) to develop and deliver novel therapies that can address genetic disorders. By leveraging the potential of mRNA technology, Mink Therapeutics aims to offer innovative treatments that have the ability to fundamentally transform the field of genetic medicine.
More about Mink Therapeutics Inc 's Market Share
|
Fresh Tracks Therapeutics Inc
Share Performance
+0.21%
30 Days
|
Fresh Tracks Therapeutics Inc
Profile
Fresh Tracks Therapeutics Inc is a biotechnology company that focuses on developing innovative therapies for various diseases. Their business model revolves around conducting research and development to discover new drug candidates, conducting clinical trials to test their effectiveness, and ultimately bringing these therapies to market through partnerships or direct sales. They aim to monetize their discoveries through licensing agreements, product sales, and collaborations with other pharmaceutical companies.
More about Fresh Tracks Therapeutics Inc 's Market Share
|
Adaptimmune Therapeutics Plc
Share Performance
+5.06%
30 Days
|
Adaptimmune Therapeutics Plc
Profile
Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.
More about Adaptimmune Therapeutics Plc's Market Share
|
Elevation Oncology inc
Share Performance
-48.02%
This Quarter
|
Elevation Oncology inc
Profile
Elevation Oncology Inc's business model focuses on precision medicine and targeted therapies for rare and genomically defined cancers.
More about Elevation Oncology inc 's Market Share
|
Avalon Globocare Corp
Share Performance
-4.07%
Over The Past 5 Days
|
Avalon Globocare Corp
Profile
Avalon Globocare Corp's business model is focused on providing innovative healthcare solutions and services through strategic acquisitions, partnerships, and collaborations in the biotechnology and healthcare sectors.
More about Avalon Globocare Corp's Market Share
|
Greenlight Biosciences Holdings Pbc
Share Performance
-85.53%
One Year
|
Greenlight Biosciences Holdings Pbc
Profile
Greenlight Biosciences Holdings Pbc's business model focuses on using proprietary cell-free bioprocessing technology to produce sustainable and environmentally friendly bio-based products.
More about Greenlight Biosciences Holdings Pbc's Market Share
|
Day One Biopharmaceuticals Inc
Share Performance
-50.67%
This Year
|
Day One Biopharmaceuticals Inc
Profile
Day One Biopharmaceuticals Inc operates with a business model focused on developing targeted therapies for patients with rare genetic diseases and cancer. They aim to leverage their expertise in precision medicine and drug discovery to create innovative treatments that address unmet medical needs. Their approach involves identifying genetic mutations and developing therapies tailored specifically to target these mutations and improve patient outcomes.
More about Day One Biopharmaceuticals Inc 's Market Share
|
Iveric Bio Inc
Share Performance
+2.96%
30 Days
|
Iveric Bio Inc
Profile
Iveric Bio Inc's business model involves the development and commercialization of innovative gene therapy treatments for the treatment of retinal diseases.
More about Iveric Bio Inc 's Market Share
|
Cyteir Therapeutics Inc
Share Performance
-0.33%
Over The Past 5 Days
|
Cyteir Therapeutics Inc
Profile
Cyteir Therapeutics Inc is a biotechnology company that focuses on developing targeted cancer therapies. Their business model is centered around the discovery and development of novel drugs that exploit DNA repair pathways to selectively kill cancer cells. They aim to bring these therapies to market and advance the field of cancer treatment through strategic partnerships and collaborations.
More about Cyteir Therapeutics Inc 's Market Share
|
Tyra Biosciences Inc
Share Performance
-46.36%
One Year
|
Tyra Biosciences Inc
Profile
Tyra Biosciences Inc follows a research and development-focused business model in the biotechnology industry. The company aims to develop innovative and cutting-edge biopharmaceutical products for various therapeutic applications. With a strong emphasis on scientific advancements, Tyra Biosciences Inc strives to bring novel solutions to market that address unmet medical needs.
More about Tyra Biosciences Inc 's Market Share
|
Biomea Fusion Inc
Share Performance
-86.55%
One Year
|
Biomea Fusion Inc
Profile
Biomea Fusion Inc operates on a business model focused on the development of precision medicine for cancer treatments. They leverage advanced genomic technologies to identify and understand specific gene fusions that drive cancer growth. By developing targeted therapies, they aim to improve patient outcomes and revolutionize cancer treatment.
More about Biomea Fusion Inc 's Market Share
|
Anixa Biosciences Inc
Share Performance
+5.49%
This Year
|
Anixa Biosciences Inc
Profile
Anixa Biosciences Inc's business model focuses on developing and commercializing innovative diagnostics and therapeutics in the field of cancer.
More about Anixa Biosciences Inc 's Market Share
|
Bioxcel Therapeutics Inc
Share Performance
-24.86%
30 Days
|
Bioxcel Therapeutics Inc
Profile
BioXcel Therapeutics Inc. is a biopharmaceutical company that operates using an innovative business model. They utilize artificial intelligence (AI) and big data analytics to identify and develop novel therapies for targeted diseases with unmet medical needs. This approach allows them to leverage data-driven insights to expedite drug discovery and development, potentially increasing the efficiency and success rate of their drug candidates.
More about Bioxcel Therapeutics Inc 's Market Share
|
Actinium Pharmaceuticals Inc
Share Performance
-80.71%
One Year
|
Actinium Pharmaceuticals Inc
Profile
Actinium Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of targeted therapies for the treatment of various cancers.
More about Actinium Pharmaceuticals Inc's Market Share
|
Checkpoint Therapeutics inc
Share Performance
+27.36%
This Year
|
Checkpoint Therapeutics inc
Profile
Checkpoint Therapeutics Inc is a biopharmaceutical company that develops and commercializes immune-targeted therapies for the treatment of cancer. The company mainly focuses on acquiring, developing, and commercializing targeted immunotherapy and immuno-oncology products. Through collaborations and strategic partnerships, Checkpoint Therapeutics aims to bring innovative and effective therapies to patients while creating value for shareholders.
More about Checkpoint Therapeutics inc 's Market Share
|
Immuneering Corporation
Share Performance
-30.32%
This Year
|
Immuneering Corporation
Profile
Immuneering Corp operates on a business model that harnesses the power of big data in the field of biomedicine. Through their proprietary technologies, they analyze vast amounts of biological data to gain insights into disease mechanisms, drug discovery, and patient care. They leverage their expertise to provide pharmaceutical companies and healthcare organizations with actionable information for accelerating the development of new therapeutics and improving clinical outcomes.
More about Immuneering Corporation's Market Share
|
Oragenics Inc
Share Performance
-91.44%
One Year
|
Oragenics Inc
Profile
Oragenics Inc's business model revolves around developing and commercializing novel technologies and products to address unmet healthcare needs.
More about Oragenics Inc 's Market Share
|
Rain Oncology Inc
Share Performance
-39.81%
Over The Past 5 Days
|
Rain Oncology Inc
Profile
Rain Therapeutics Inc is a biopharmaceutical company that focuses on discovering and developing precision oncology therapies. Their business model revolves around identifying genetic alterations and biomarkers in cancer patients, and then developing targeted therapies to address these specific alterations. By tailoring treatments to individual patients, they aim to improve outcomes and provide more effective and personalized cancer care.
More about Rain Oncology Inc 's Market Share
|
9 Meters Biopharma Inc
Share Performance
-94.22%
This Quarter
|
9 Meters Biopharma Inc
Profile
9 Meters Biopharma Inc is a pharmaceutical company that focuses on developing and commercializing innovative therapies for gastrointestinal diseases. Their business model revolves around conducting research, clinical trials, and gaining regulatory approvals for their drug candidates. They then aim to license or partner with larger pharmaceutical companies for manufacturing, marketing, and distribution of their approved treatments.
More about 9 Meters Biopharma Inc 's Market Share
|
Erasca Inc
Share Performance
-12.86%
30 Days
|
Erasca Inc
Profile
Erasca Inc is a biotechnology company that focuses on discovering and developing innovative therapies for cancer. Their business model revolves around leveraging cutting-edge technologies and scientific expertise to identify and advance multiple drug candidates simultaneously. By collaborating with academic institutions and biopharmaceutical partners, Erasca aims to accelerate the development of cancer treatments to improve patient outcomes.
More about Erasca Inc 's Market Share
|
Kinnate Biopharma Inc
Share Performance
+0.76%
Over The Past 5 Days
|
Kinnate Biopharma Inc
Profile
Kinnate Biopharma Inc is a company that focuses on developing targeted therapies for genetically-defined cancers.
More about Kinnate Biopharma Inc 's Market Share
|
Alx Oncology Holdings Inc
Share Performance
-22.85%
30 Days
|
Alx Oncology Holdings Inc
Profile
Alx Oncology Holdings Inc's business model is centered around the development and commercialization of innovative cancer therapeutics.
More about Alx Oncology Holdings Inc's Market Share
|
Zentalis Pharmaceuticals Inc
Share Performance
-89.35%
One Year
|
Zentalis Pharmaceuticals Inc
Profile
Zentalis Pharmaceuticals Inc is a biopharmaceutical company that focuses on the discovery and development of small molecule therapies for the treatment of various types of cancer. Their business model revolves around leveraging their expertise in drug discovery, conducting clinical trials, and ultimately commercializing effective cancer treatments. By leveraging their innovative research and development capabilities, Zentalis aims to address unmet medical needs and improve the lives of cancer patients worldwide.
More about Zentalis Pharmaceuticals Inc 's Market Share
|
Trevi Therapeutics Inc
Share Performance
+44.27%
This Year
|
Trevi Therapeutics Inc
Profile
Trevi Therapeutics Inc is a biopharmaceutical company that specializes in developing therapies for neurologically mediated conditions. Their business model focuses on identifying and developing innovative treatment options that target specific receptors in the nervous system. By leveraging their expertise in neuroscience and drug development, Trevi aims to bring novel therapies to market and improve the lives of patients suffering from these conditions.
More about Trevi Therapeutics Inc 's Market Share
|
Viking Therapeutics Inc
Share Performance
-57.00%
One Year
|
Viking Therapeutics Inc
Profile
Viking Therapeutics Inc is a biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders.
More about Viking Therapeutics Inc 's Market Share
|
Pds Biotechnology Corp
Share Performance
-8.67%
This Year
|
Pds Biotechnology Corp
Profile
Pds Biotechnology Corp is a biotechnology company that focuses on developing innovative immunotherapies for the treatment of various cancers and infectious diseases. Their business model revolves around leveraging their proprietary Versamune? platform to design and develop novel vaccines and immunotherapies with enhanced efficacy compared to traditional approaches. Pds Biotechnology Corp also collaborates with pharmaceutical companies and research institutions to advance their product pipeline and explore potential applications of their technology.
More about Pds Biotechnology Corp's Market Share
|
Omeros Corporation
Share Performance
-5.67%
One Year
|
Omeros Corporation
Profile
Omeros Corporation operates under a business model focused on the research, development, and commercialization of pharmaceutical products. Their core strategy involves leveraging their expertise in biochemistry and pharmacology to identify and target specific therapeutic areas with high unmet medical needs. By conducting clinical trials and seeking regulatory approvals, Omeros aims to bring their innovative products to market and generate revenue through commercial sales.
More about Omeros Corporation's Market Share
|
Repare Therapeutics Inc
Share Performance
0.00%
This Year
|
Repare Therapeutics Inc
Profile
Repare Therapeutics Inc is a biotechnology company that specializes in the development of precision oncology drugs. Their business model focuses on leveraging synthetic lethality, a targeted therapy approach, to identify and develop small molecule drugs for the treatment of various forms of cancer. By discovering and advancing novel therapeutics, Repare Therapeutics aims to improve patient outcomes and address unmet medical needs in oncology.
More about Repare Therapeutics Inc 's Market Share
|
Essa Pharma inc
Share Performance
-0.59%
Over The Past 5 Days
|
Essa Pharma inc
Profile
Essa Pharma Inc.'s business model revolves around the development of targeted small molecule therapeutics for the treatment of cancer. The company aims to address the unmet medical needs of patients with advanced and metastatic forms of prostate and breast cancer. By leveraging their expertise in clinical development and precision medicine, Essa Pharma aspires to bring innovative and effective treatments to market, ultimately improving patient outcomes.
More about Essa Pharma inc 's Market Share
|
Kura Oncology Inc
Share Performance
-9.62%
Over The Past 5 Days
|
Kura Oncology Inc
Profile
Kura Oncology Inc is a biotechnology company that focuses on the discovery and development of precision medicines for the treatment of cancer. Their business model revolves around leveraging their expertise in oncology to identify and design small molecule drug candidates that target specific genetic mutations or biomarkers. Through strategic partnerships and collaborations, Kura aims to advance their drug candidates through clinical studies and ultimately commercialize these precision medicines for patients in need.
More about Kura Oncology Inc 's Market Share
|
Sonnet Biotherapeutics Holdings Inc
Share Performance
-21.53%
This Quarter
|
Sonnet Biotherapeutics Holdings Inc
Profile
Sonnet Biotherapeutics Holdings Inc's business model revolves around the development and commercialization of innovative immunotherapies for the treatment of cancer and other diseases.
More about Sonnet Biotherapeutics Holdings Inc 's Market Share
|
Portage Biotech Inc
Share Performance
+72.65%
This Quarter
|
Portage Biotech Inc
Profile
Portage Biotech Inc.'s business model involves the identification and development of innovative therapeutics and healthcare solutions, leveraging a unique portfolio of biotechnology companies and their technologies.
More about Portage Biotech Inc 's Market Share
|
Shattuck Labs Inc
Share Performance
+28.89%
30 Days
|
Shattuck Labs Inc
Profile
Shattuck Labs Inc operates through a platform-based business model, focusing on the development of biotechnology products and solutions. By utilizing its proprietary technology and expertise, the company aims to create innovative therapies targeting various diseases and disorders, ultimately improving patient outcomes. Shattuck Labs Inc collaborates with strategic partners and stakeholders to advance its pipeline, aiming to commercialize its novel treatments and drive growth in the biotech industry.
More about Shattuck Labs Inc 's Market Share
|
Acadia Pharmaceuticals Inc
Share Performance
+10.18%
This Quarter
|
Acadia Pharmaceuticals Inc
Profile
Acadia Pharmaceuticals Inc's business model centers around the research, development, and commercialization of innovative medicines for diseases related to the central nervous system. They collaborate with a network of partners and employ a combination of in-house research and licensing agreements to discover and develop drug candidates. Their primary revenue stream comes from the sales of approved products, with a focus on providing effective therapeutic options for patients with unmet medical needs.
More about Acadia Pharmaceuticals Inc 's Market Share
|
Vanda Pharmaceuticals Inc
Share Performance
-10.17%
This Year
|
Vanda Pharmaceuticals Inc
Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of innovative therapies for central nervous system disorders. Their business model revolves around conducting research and development activities to identify potential drug candidates, securing intellectual property rights, and seeking regulatory approvals for the commercialization of their products. Through partnerships and collaborations, they aim to bring their novel therapies to market and improve the lives of patients suffering from neurological disorders.
More about Vanda Pharmaceuticals Inc 's Market Share
|
Amgen Inc
Share Performance
+4.77%
This Year
|
Amgen Inc
Profile
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
More about Amgen Inc 's Market Share
|
Regeneron Pharmaceuticals Inc
Share Performance
-15.99%
This Quarter
|
Regeneron Pharmaceuticals Inc
Profile
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
More about Regeneron Pharmaceuticals Inc 's Market Share
|
Astrazeneca Plc
Share Performance
+1.24%
30 Days
|
Astrazeneca Plc
Profile
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
More about Astrazeneca Plc's Market Share
|
Biogen Inc
Share Performance
-2.80%
Over The Past 5 Days
|
Biogen Inc
Profile
Biogen Incs business model focuses on researching, developing, and commercializing innovative therapies primarily for neurological and neurodegenerative diseases, emphasizing advancements in precision medicine and patient care.
More about Biogen Inc 's Market Share
|
Vertex Pharmaceuticals Inc
Share Performance
+7.45%
This Year
|
Vertex Pharmaceuticals Inc
Profile
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
More about Vertex Pharmaceuticals Inc's Market Share
|
Seagen Inc
Share Performance
+10.32%
This Quarter
|
Seagen Inc
Profile
Seagen Inc is a biotechnology company that focuses on developing and commercializing innovative cancer therapeutics. Their business model revolves around research and development of targeted antibody-based drugs, specifically using their proprietary antibody-drug conjugate (ADC) technology. Seagen Inc also seeks strategic collaborations and partnerships with other pharmaceutical companies to enhance their product pipeline and expand their market reach.
More about Seagen Inc 's Market Share
|
Shuttle Pharmaceuticals Holdings Inc
Share Performance
-16.02%
Over The Past 5 Days
|
Shuttle Pharmaceuticals Holdings Inc
Profile
Shuttle Pharmaceuticals Holdings Inc is a pharmaceutical company that operates on a business-to-business (B2B) model. They develop and manufacture a wide range of pharmaceutical products and then distribute them to other companies or medical institutions for further distribution or use. Their primary focus is on ensuring the quality and effectiveness of their products while partnering with other entities to ensure their widespread availability in the market.
More about Shuttle Pharmaceuticals Holdings Inc 's Market Share
|
Supernus Pharmaceuticals inc
Share Performance
+2.39%
30 Days
|
Supernus Pharmaceuticals inc
Profile
Supernus Pharmaceuticals Inc operates under a unique business model focused on the development and commercialization of innovative treatments for central nervous system (CNS) diseases. The company combines in-house expertise with strategic partnerships to efficiently advance and bring their products to market. By prioritizing CNS disorders and utilizing a collaborative approach, Supernus Pharmaceuticals strives to address unmet medical needs and improve the lives of patients.
More about Supernus Pharmaceuticals inc 's Market Share
|
Bioxytran Inc
Share Performance
+85.56%
This Year
|
Bioxytran Inc
Profile
Bioxytran Inc's business model revolves around developing and commercializing innovative therapeutic solutions, specifically focusing on oxygen therapeutics for various medical applications.
More about Bioxytran Inc 's Market Share
|
Deciphera Pharmaceuticals Inc
Share Performance
+54.62%
This Year
|
Deciphera Pharmaceuticals Inc
Profile
Deciphera Pharmaceuticals Inc's business model revolves around the research, development, and commercialization of precision medicines for the treatment of cancer and other serious diseases.
More about Deciphera Pharmaceuticals Inc 's Market Share
|
Reata Pharmaceuticals Inc
Share Performance
+369.52%
This Year
|
Reata Pharmaceuticals Inc
Profile
Reata Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapeutics for serious and life-threatening diseases. Their business model centers around the discovery, development, and commercialization of novel drugs based on their proprietary technology platform. Reata Pharmaceuticals aims to bring transformative treatments to patients, partnering with other organizations and leveraging their expertise to deliver value to stakeholders.
More about Reata Pharmaceuticals Inc 's Market Share
|
Olema Pharmaceuticals Inc
Share Performance
-9.52%
This Year
|
Olema Pharmaceuticals Inc
Profile
Olema Pharmaceuticals Inc.'s business model focuses on the research, development, and commercialization of innovative cancer therapies.
More about Olema Pharmaceuticals Inc 's Market Share
|
Surface Oncology Inc
Share Performance
+31.24%
This Year
|
Surface Oncology Inc
Profile
Surface Oncology Inc is a biotechnology company focused on developing innovative immunotherapies to treat cancer. They employ a research-driven approach to identify and target novel immune checkpoints and design therapeutic antibodies to activate the immune system against tumors. Their business model revolves around conducting preclinical and clinical research, collaborating with strategic partners, and licensing or commercializing their products to bring new treatment options to patients.
More about Surface Oncology Inc 's Market Share
|
Oncosec Medical Incorporated
Share Performance
-85.64%
This Quarter
|
Oncosec Medical Incorporated
Profile
Oncosec Medical Incorporated's business model revolves around developing and commercializing innovative immunotherapies for the treatment of various cancers.
More about Oncosec Medical Incorporated's Market Share
|
Curis Inc
Share Performance
-35.48%
This Quarter
|
Curis Inc
Profile
Curis Inc's business model revolves around the development and commercialization of innovative cancer therapies. They focus on discovering and advancing drug candidates targeting specific molecular pathways involved in cancer growth and survival. The company collaborates with pharmaceutical partners to conduct clinical trials and seek regulatory approval for their products.
More about Curis Inc 's Market Share
|
Precigen Inc
Share Performance
+0.74%
One Year
|
Precigen Inc
Profile
Precigen Inc is a biotechnology company that focuses on the development and commercialization of innovative genetic therapies. Their business model revolves around leveraging their proprietary technologies and expertise in gene editing and synthetic biology to create transformative medical solutions. With a strong emphasis on research and development, Precigen aims to bring cutting-edge genetic therapies to market and address critical unmet medical needs.
More about Precigen Inc 's Market Share
|
Intercept Pharmaceuticals inc
Share Performance
+51.64%
This Year
|
Intercept Pharmaceuticals inc
Profile
Intercept Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics in the field of chronic liver diseases. Their business model revolves around identifying and targeting specific liver diseases with high unmet medical needs, conducting extensive research and clinical trials to develop effective therapies, and then commercializing these drugs globally to generate sustainable revenue streams. By addressing liver diseases with innovative treatments, Intercept aims to improve patient outcomes and establish a profitable position in the pharmaceutical industry.
More about Intercept Pharmaceuticals inc 's Market Share
|
X4 Pharmaceuticals Inc
Share Performance
-88.56%
One Year
|
X4 Pharmaceuticals Inc
Profile
X4 Pharmaceuticals Inc is a biopharmaceutical company focused on the research and development of innovative treatments for rare diseases, particularly those involving the immune system and rare genetic disorders. Their business model revolves around identifying potential drug candidates, conducting preclinical and clinical trials, and ultimately bringing these therapies to market to improve patient outcomes.
More about X4 Pharmaceuticals Inc's Market Share
|
Nurix Therapeutics Inc
Share Performance
-15.63%
30 Days
|
Nurix Therapeutics Inc
Profile
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
More about Nurix Therapeutics Inc 's Market Share
|
Mural Oncology Plc
Share Performance
-23.40%
One Year
|
Mural Oncology Plc
Profile
Mural Oncology Plc's business model focuses on developing and commercializing innovative cancer therapies. They likely collaborate with research institutes and pharmaceutical companies to acquire promising drug candidates and conduct rigorous clinical trials. Their revenue is generated through licensing, partnerships, and potential product sales, helping provide solutions for patients suffering from various forms of cancer.
More about Mural Oncology Plc's Market Share
|
Adicet Bio Inc
Share Performance
-1.71%
Over The Past 5 Days
|
Adicet Bio Inc
Profile
Adicet Bio Inc's business model involves the development and commercialization of cell therapy medications for various diseases.
More about Adicet Bio Inc 's Market Share
|
Regenerx Biopharmaceuticals inc
Share Performance
0.00%
30 Days
|
Regenerx Biopharmaceuticals inc
Profile
Regenerx Biopharmaceuticals Inc operates with a business model based on developing and commercializing innovative therapeutic products. They focus on utilizing regenerative medicine to address unmet medical needs in various therapeutic areas, including ophthalmology and dermatology. The company aims to identify promising drug candidates, conduct clinical trials, and ultimately bring their products to market to improve patients' lives.
More about Regenerx Biopharmaceuticals inc 's Market Share
|
Ibio inc
Share Performance
-3.42%
30 Days
|
Ibio inc
Profile
Ibio Inc is a plant-based biologics company that focuses on the development and manufacturing of therapeutic proteins. They utilize their proprietary plant-based expression system to produce biotherapeutics quickly and cost-effectively. By leveraging their platform, Ibio aims to address unmet medical needs and provide affordable and accessible treatments to patients worldwide.
More about Ibio inc 's Market Share
|
Mustang Bio inc
Share Performance
+0.81%
30 Days
|
Mustang Bio inc
Profile
Mustang Bio Inc operates on a business model focused on developing advanced therapies for challenging diseases. They primarily engage in research, development, and commercialization of innovative gene and cell therapies. Mustang Bio Inc aims to provide cutting-edge treatments to patients in need by leveraging its expertise in gene editing technologies and strategic partnerships.
More about Mustang Bio inc 's Market Share
|
Sensei Biotherapeutics Inc
Share Performance
-42.62%
This Year
|
Sensei Biotherapeutics Inc
Profile
Sensei Biotherapeutics Inc is a biotechnology company that focuses on developing personalized and targeted cancer therapies. They employ a unique approach called ImmunoPhage, which utilizes bacteriophages to specifically target tumor antigens and stimulate an immune response. Their business model revolves around conducting research and clinical trials to bring innovative cancer treatment options to market.
More about Sensei Biotherapeutics Inc 's Market Share
|
Nanobiotix S a
Share Performance
-7.37%
This Quarter
|
Nanobiotix S a
Profile
Nanobiotix S is a company that operates in the field of nanomedicine and innovative therapeutic solutions. Their business model revolves around the development and commercialization of nanotechnology-based products for cancer treatment. They aim to leverage their proprietary technology to deliver targeted and optimized treatments, potentially improving patient outcomes and transforming cancer therapy.
More about Nanobiotix S a 's Market Share
|
Io Biotech Inc
Share Performance
+31.12%
30 Days
|
Io Biotech Inc
Profile
Io Biotech Inc's business model focuses on the development and commercialization of innovative immuno-oncology therapies.
More about Io Biotech Inc 's Market Share
|
Lixte Biotechnology Holdings Inc
Share Performance
+5.10%
30 Days
|
Lixte Biotechnology Holdings Inc
Profile
Lixte Biotechnology Holdings Inc is a biotech company that focuses on the discovery and development of novel drugs for the treatment of cancer. They primarily operate by conducting pre-clinical and clinical studies, as well as collaborating with research institutions and pharmaceutical companies to advance their drug candidates.
More about Lixte Biotechnology Holdings Inc 's Market Share
|
I mab
Share Performance
+8.68%
Over The Past 5 Days
|
I mab
Profile
The I Mab business model focuses on the development and commercialization of innovative biopharmaceutical products. They specialize in the research and development of novel antibodies and other therapeutic agents to address unmet medical needs. By collaborating with strategic partners and leveraging their expertise in drug discovery and clinical development, I Mab aims to bring transformative treatments to patients globally.
More about I mab's Market Share
|
Xortx Therapeutics inc
Share Performance
+15.99%
This Quarter
|
Xortx Therapeutics inc
Profile
Xortx Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for the treatment of kidney diseases.
More about Xortx Therapeutics inc 's Market Share
|
Corvus Pharmaceuticals Inc
Share Performance
-4.64%
30 Days
|
Corvus Pharmaceuticals Inc
Profile
Corvus Pharmaceuticals Inc operates under a business model focused on developing and commercializing novel immuno-oncology therapies. They aim to leverage their expertise in the field to identify and develop innovative anticancer drugs that target specific immune checkpoints. By collaborating with academic institutions and industry partners, Corvus Pharmaceuticals seeks to bring transformative treatments to patients in need.
More about Corvus Pharmaceuticals Inc 's Market Share
|
Spruce Biosciences Inc
Share Performance
-85.00%
This Quarter
|
Spruce Biosciences Inc
Profile
Spruce Biosciences Inc's business model focuses on developing and commercializing novel therapies for rare endocrine disorders.
More about Spruce Biosciences Inc 's Market Share
|
Carisma Therapeutics Inc
Share Performance
-2.73%
Over The Past 5 Days
|
Carisma Therapeutics Inc
Profile
Carisma Therapeutics Inc's business model focuses on developing novel CAR-Macrophage cell therapies to treat solid tumors. They aim to leverage their proprietary technology platform to engineer immune cells that can effectively target and destroy cancer cells, while also optimizing the manufacturing process for scalability and cost-effectiveness.
More about Carisma Therapeutics Inc 's Market Share
|
Lumos Pharma Inc
Share Performance
-0.69%
30 Days
|
Lumos Pharma Inc
Profile
Lumos Pharma Inc is a biopharmaceutical company that focuses on developing therapeutics for rare diseases. Their business model revolves around identifying and repurposing existing drugs to create innovative treatments for patients with unmet medical needs in the rare disease space.
More about Lumos Pharma Inc 's Market Share
|
Mersana Therapeutics inc
Share Performance
-33.93%
This Quarter
|
Mersana Therapeutics inc
Profile
Mersana Therapeutics Inc's business model focuses on developing and commercializing novel antibody-drug conjugates (ADCs) for the treatment of cancer.
More about Mersana Therapeutics inc 's Market Share
|
Enlivex Therapeutics Ltd
Share Performance
-30.36%
One Year
|
Enlivex Therapeutics Ltd
Profile
Enlivex Therapeutics Ltd's business model focuses on developing and commercializing novel immune system therapies.
More about Enlivex Therapeutics Ltd 's Market Share
|
G1 Therapeutics Inc
Share Performance
+129.90%
This Year
|
G1 Therapeutics Inc
Profile
G1 Therapeutics Inc is a biopharmaceutical company that operates under a research and development business model. They focus on discovering, developing, and commercializing novel therapies to address unmet needs in cancer treatment, with a strong emphasis on targeting specific cellular processes. Their business model involves conducting preclinical and clinical trials, obtaining regulatory approvals, and collaborating with strategic partners to bring their innovative drugs to market.
More about G1 Therapeutics Inc 's Market Share
|
Leap Therapeutics Inc
Share Performance
-7.25%
30 Days
|
Leap Therapeutics Inc
Profile
Leap Therapeutics Inc. is a biopharmaceutical company with a business model focused on discovering and developing targeted therapies for cancer. They aim to leverage their expertise in identifying novel targets and developing antibody-based therapies to address unmet medical needs in oncology. By advancing their pipeline of innovative drugs, they seek to provide effective treatment options for patients and create value for stakeholders in the pharmaceutical industry.
More about Leap Therapeutics Inc 's Market Share
|
Gain Therapeutics inc
Share Performance
-25.62%
One Year
|
Gain Therapeutics inc
Profile
Gain Therapeutics inc's business model revolves around using cutting-edge technology and innovative approaches to identify and develop small molecules that can effectively target and treat rare genetic diseases, such as lysosomal storage disorders and CNS-related disorders. They aim to leverage their expertise in computational drug design and protein structure analysis to discover potential drug candidates, which can then be developed and commercialized for therapeutic purposes.
More about Gain Therapeutics inc's Market Share
|
Cyclerion Therapeutics Inc
Share Performance
+8.64%
30 Days
|
Cyclerion Therapeutics Inc
Profile
Cyclerion Therapeutics Inc's business model focuses on developing and commercializing innovative therapies for serious and chronic diseases by targeting soluble guanylate cyclase (sGC).
More about Cyclerion Therapeutics Inc 's Market Share
|
Lantern Pharma Inc
Share Performance
-47.53%
One Year
|
Lantern Pharma Inc
Profile
Lantern Pharma Inc's business model focuses on leveraging artificial intelligence and machine learning to identify and repurpose existing drugs for the treatment of various diseases.
More about Lantern Pharma Inc 's Market Share
|
Tempest Therapeutics Inc
Share Performance
-44.30%
This Quarter
|
Tempest Therapeutics Inc
Profile
Tempest Therapeutics Inc is a biotechnology company focused on developing small molecule therapeutics to treat cancer and other diseases. Their business model revolves around identifying novel targets within the immune system and designing drugs that modulate these targets to enhance the body's immune response against cancer cells. Through strategic collaborations and partnerships, they aim to accelerate the development and commercialization of their product candidates.
More about Tempest Therapeutics Inc 's Market Share
|
Acrivon Therapeutics Inc
Share Performance
-85.28%
One Year
|
Acrivon Therapeutics Inc
Profile
Acrivon Therapeutics Inc's business model focuses on developing and commercializing innovative therapeutics in the healthcare industry.
More about Acrivon Therapeutics Inc 's Market Share
|
Marker Therapeutics inc
Share Performance
-64.15%
This Year
|
Marker Therapeutics inc
Profile
Marker Therapeutics Inc is a biotechnology company that aims to develop and commercialize novel T cell immunotherapies for the treatment of cancer. Their business model focuses on leveraging their expertise in cellular engineering to develop proprietary technologies and therapies that can be licensed or partnered with other organizations for further development and commercialization.
More about Marker Therapeutics inc 's Market Share
|
Foghorn Therapeutics Inc
Share Performance
-7.38%
30 Days
|
Foghorn Therapeutics Inc
Profile
Foghorn Therapeutics Inc is a biotechnology company focused on discovering and developing drugs that target the chromatin regulatory system to treat a range of diseases. The company utilizes its proprietary Gene Traffic Control platform to identify and validate new therapeutic targets related to the modulation of gene expression.
More about Foghorn Therapeutics Inc 's Market Share
|
Mei Pharma Inc
Share Performance
-15.49%
This Year
|
Mei Pharma Inc
Profile
Mei Pharma Inc's business model focuses on developing and commercializing novel therapies for the treatment of cancer.
More about Mei Pharma Inc 's Market Share
|
Aprea Therapeutics Inc
Share Performance
-68.48%
One Year
|
Aprea Therapeutics Inc
Profile
Aprea Therapeutics Inc is a biopharmaceutical company with a business model focused on developing and commercializing innovative cancer therapies. They aim to leverage their proprietary discovery platform to identify and develop small molecules that selectively target and restore the tumor suppressor protein p53. Their business strategy includes conducting clinical trials, seeking regulatory approvals, and partnering with other organizations for commercialization and distribution.
More about Aprea Therapeutics Inc 's Market Share
|
Immix Biopharma Inc
Share Performance
+13.71%
30 Days
|
Immix Biopharma Inc
Profile
ImmIx Biopharma Inc is a biotechnology company that focuses on developing novel therapeutics for the treatment of cancer. Their business model involves conducting extensive research and development to discover and optimize drug candidates, followed by preclinical and clinical testing to assess their safety and effectiveness. They aim to collaborate with pharmaceutical companies or seek licensing agreements to further develop and commercialize their biopharmaceutical products.
More about Immix Biopharma Inc 's Market Share
|
Oncternal Therapeutics Inc
Share Performance
-89.68%
One Year
|
Oncternal Therapeutics Inc
Profile
Oncternal Therapeutics Inc's business model focuses on developing and commercializing novel therapies for the treatment of cancer.
More about Oncternal Therapeutics Inc 's Market Share
|
Y mabs Therapeutics inc
Share Performance
-45.80%
This Year
|
Y mabs Therapeutics inc
Profile
Ymabs Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for the treatment of cancer.
More about Y mabs Therapeutics inc 's Market Share
|
Syros Pharmaceuticals Inc
Share Performance
+2.64%
Over The Past 5 Days
|
Syros Pharmaceuticals Inc
Profile
Syros Pharmaceuticals Inc operates based on a business model focused on developing targeted gene control therapies to treat various diseases. The company aims to leverage its gene control platform to identify and exploit unique gene regulatory networks to discover and develop novel therapeutics.
More about Syros Pharmaceuticals Inc 's Market Share
|
Cti Biopharma Corp
Share Performance
+56.19%
One Year
|
Cti Biopharma Corp
Profile
CTI Biopharma Corp is a biopharmaceutical company that specializes in the development and commercialization of novel oncology therapies.
More about Cti Biopharma Corp 's Market Share
|
Nuvectis Pharma inc
Share Performance
-10.31%
30 Days
|
Nuvectis Pharma inc
Profile
Nuvectis Pharma Inc's business model appears to focus on the development and commercialization of pharmaceutical products.
More about Nuvectis Pharma inc 's Market Share
|
Neximmune Inc
Share Performance
-99.92%
This Year
|
Neximmune Inc
Profile
Neximmune Inc is a biotechnology company that focuses on developing personalized immunotherapies to treat various cancers and autoimmune diseases.
More about Neximmune Inc 's Market Share
|
Enliven Therapeutics Inc
Share Performance
-24.77%
This Quarter
|
Enliven Therapeutics Inc
Profile
Enliven Therapeutics Inc's business model focuses on developing and providing effective therapeutic solutions that enhance patient wellness and quality of life.
More about Enliven Therapeutics Inc 's Market Share
|
Urogen Pharma Ltd
Share Performance
-58.56%
30 Days
|
Urogen Pharma Ltd
Profile
Urogen Pharma Ltd is a pharmaceutical company that specializes in developing and commercializing innovative therapies for urological and oncological conditions. Their business model revolves around conducting extensive research and development to create novel therapies, obtaining necessary regulatory approvals, and strategically partnering with healthcare providers and other stakeholders to market and distribute their products globally. By focusing on addressing unmet medical needs in the urology field, Urogen Pharma aims to improve patient outcomes and establish a strong presence in the market.
More about Urogen Pharma Ltd 's Market Share
|
Celcuity Inc
Share Performance
-33.25%
One Year
|
Celcuity Inc
Profile
Celcuity Inc is a biotechnology company that develops and commercializes diagnostic tests designed to classify patients' specific cancer subtypes. These tests help physicians select the most appropriate targeted therapies for their patients, ultimately improving treatment outcomes.
More about Celcuity Inc 's Market Share
|
Xoma Royalty Corporation
Share Performance
-9.57%
Over The Past 5 Days
|
Xoma Royalty Corporation
Profile
Xoma Corporation operates under a business model focused on the development and commercialization of novel therapeutics. The company primarily concentrates on creating antibody-based therapies to address unmet medical needs. Xoma also engages in collaborations and partnerships with other pharmaceutical companies to advance their product pipeline and expand their reach in the market.
More about Xoma Royalty Corporation's Market Share
|
Merus N v
Share Performance
+30.35%
This Year
|
Merus N v
Profile
Merus N V is a biotechnology company that operates using a differentiated and competitive business model. Their approach involves strategically targeting and developing bispecific antibodies to treat various types of cancer, leveraging their proprietary technologies and expertise in the field. By focusing on innovative research, efficient drug discovery, and partnerships, they aim to improve patient outcomes and drive growth in the oncology market.
More about Merus N v 's Market Share
|
Ideaya Biosciences Inc
Share Performance
-25.20%
This Year
|
Ideaya Biosciences Inc
Profile
Ideaya Biosciences Inc operates on a precision medicine approach that combines genomics and synthetic lethality to develop targeted cancer therapies. The company focuses on identifying synthetic lethal interactions in cancer and leveraging these insights to discover and develop drugs that selectively target cancer cells. They collaborate with academic institutions and industry partners to advance their therapeutic pipeline and bring innovative treatments to patients in need.
More about Ideaya Biosciences Inc 's Market Share
|
Praxis Precision Medicines Inc
Share Performance
+4.31%
30 Days
|
Praxis Precision Medicines Inc
Profile
Praxis Precision Medicines Inc's business model revolves around developing precision medicines for the treatment of various central nervous system (CNS) disorders.
More about Praxis Precision Medicines Inc 's Market Share
|
Chinook Therapeutics Inc
Share Performance
+58.77%
This Year
|
Chinook Therapeutics Inc
Profile
Chinook Therapeutics is a biotechnology company focused on the development of precision medicines for kidney diseases and other rare disorders. Their business model revolves around identifying and targeting specific pathways involved in the progression of kidney diseases, leveraging innovative technologies and partnerships to develop novel therapies that can improve patient outcomes. By prioritizing the unmet needs in the field of kidney diseases, Chinook aims to deliver transformative treatments to patients while creating value for their stakeholders.
More about Chinook Therapeutics Inc 's Market Share
|
Soleno Therapeutics Inc
Share Performance
+1.73%
Over The Past 5 Days
|
Soleno Therapeutics Inc
Profile
Soleno Therapeutics Inc's business model focuses on the development and commercialization of innovative therapeutics for rare diseases. They aim to identify and address unmet medical needs in the market by conducting clinical trials and seeking regulatory approval for their investigational drugs. The company is committed to advancing its portfolio of therapeutics and establishing strategic partnerships to enhance its product development and commercialization efforts.
More about Soleno Therapeutics Inc's Market Share
|
Rhythm Pharmaceuticals inc
Share Performance
+3.81%
This Year
|
Rhythm Pharmaceuticals inc
Profile
Rhythm Pharmaceuticals Inc's business model focuses on developing and commercializing therapies for rare genetic disorders that result in unmet medical needs.
More about Rhythm Pharmaceuticals inc 's Market Share
|
Nuvalent Inc
Share Performance
+0.25%
Over The Past 5 Days
|
Nuvalent Inc
Profile
Nuvalent Inc's business model entails developing innovative pharmaceutical solutions utilizing its proprietary technology and expertise.
More about Nuvalent Inc 's Market Share
|
Adc Therapeutics Sa
Share Performance
+3.85%
Over The Past 5 Days
|
Adc Therapeutics Sa
Profile
Adc Therapeutics Sa is a biotechnology company that focuses on the development and commercialization of antibody drug conjugates (ADCs) for the treatment of cancer. Their business model revolves around using their proprietary pyrrolobenzodiazepine (PBD) technology to create highly potent ADCs that selectively target cancer cells while minimizing damage to healthy cells. They aim to collaborate with global pharmaceutical companies to co-develop and potentially commercialize their ADC candidates, generating revenue through licensing agreements and milestone payments.
More about Adc Therapeutics Sa's Market Share
|
Adagene Inc
Share Performance
+2.82%
Over The Past 5 Days
|
Adagene Inc
Profile
Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.
More about Adagene Inc 's Market Share
|
Durect Corp
Share Performance
-16.27%
Over The Past 5 Days
|
Durect Corp
Profile
Durect Corp operates as a specialty pharmaceutical company that develops and commercializes innovative products for the treatment of chronic diseases. Their business model revolves around the research, development, and commercialization of their proprietary drug delivery technologies and therapeutics to address unmet medical needs.
More about Durect Corp's Market Share
|
Ligand Pharmaceuticals Incorporated
Share Performance
-6.29%
This Year
|
Ligand Pharmaceuticals Incorporated
Profile
Ligand Pharmaceuticals Inc operates on a business model focused on discovering and acquiring new drugs and technologies to license them to pharmaceutical companies. They generate revenue through licensing fees, milestone payments, and royalties from the sales of their partnered products. Their approach allows them to leverage their expertise and resources while minimizing risk, ultimately leading to long-term value creation for their shareholders.
More about Ligand Pharmaceuticals Incorporated's Market Share
|
United Therapeutics Corporation
Share Performance
+12.74%
One Year
|
United Therapeutics Corporation
Profile
United Therapeutics Corporation's business model revolves around the development and commercialization of innovative therapeutics for treating rare diseases and chronic conditions. They focus on researching, manufacturing, marketing, and distributing their specialized pharmaceutical and medical products to healthcare providers and patients globally.
More about United Therapeutics Corporation's Market Share
|
Janux Therapeutics Inc
Share Performance
-21.36%
30 Days
|
Janux Therapeutics Inc
Profile
Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.
More about Janux Therapeutics Inc 's Market Share
|
Pyxis Oncology Inc
Share Performance
+12.84%
30 Days
|
Pyxis Oncology Inc
Profile
Pyxis Oncology Inc is a biotechnology company focused on developing innovative cancer therapies. Their business model revolves around leveraging novel insights into the immune system to develop a pipeline of potential immunotherapies for cancer treatment. Pyxis Oncology aims to collaborate with strategic partners to advance their therapies through preclinical and clinical development, ultimately aiming to improve patient outcomes in the field of oncology.
More about Pyxis Oncology Inc 's Market Share
|
Bristol myers Squibb Company
Share Performance
-16.08%
This Quarter
|
Bristol myers Squibb Company
Profile
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
More about Bristol myers Squibb Company's Market Share
|
Greenwich Lifesciences Inc
Share Performance
-26.79%
One Year
|
Greenwich Lifesciences Inc
Profile
Greenwich Lifesciences Inc's business model focuses on the research, development, and commercialization of innovative therapies in the field of oncology.
More about Greenwich Lifesciences Inc 's Market Share
|
Rani Therapeutics Holdings Inc
Share Performance
-62.84%
This Quarter
|
Rani Therapeutics Holdings Inc
Profile
Rani Therapeutics Holdings Inc utilizes a novel approach in developing therapeutics by delivering large molecules orally, avoiding the need for injections.
More about Rani Therapeutics Holdings Inc 's Market Share
|
Nektar Therapeutics
Share Performance
-5.88%
Over The Past 5 Days
|
Nektar Therapeutics
Profile
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
More about Nektar Therapeutics's Market Share
|
Mannkind Corporation
Share Performance
-37.58%
This Year
|
Mannkind Corporation
Profile
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
More about Mannkind Corporation's Market Share
|
Immunogen inc
Share Performance
+5.29%
This Year
|
Immunogen inc
Profile
Immunogen Inc is a biotechnology company that focuses on the development of antibody-drug conjugates (ADCs) for the treatment of various types of cancer. Their business model is centered around leveraging their proprietary technology platform to create ADCs that deliver potent cancer-killing agents directly to tumor cells. By partnering with pharmaceutical companies, Immunogen aims to advance their ADC candidates through clinical trials and ultimately bring them to market, aiming to improve the lives of cancer patients.
More about Immunogen inc 's Market Share
|
Rigel Pharmaceuticals Inc
Share Performance
-5.67%
This Quarter
|
Rigel Pharmaceuticals Inc
Profile
Rigel Pharmaceuticals Inc is a biotechnology company that operates on a research and development business model. They focus on discovering, developing, and commercializing innovative small molecule drugs to address unmet medical needs. Their goal is to use their scientific expertise and strategic partnerships to bring new treatments to patients in various therapeutic areas.
More about Rigel Pharmaceuticals Inc's Market Share
|
Arvinas Inc
Share Performance
-0.31%
Over The Past 5 Days
|
Arvinas Inc
Profile
Arvinas Inc's business model revolves around developing novel therapies based on protein degradation technology to address unmet medical needs.
More about Arvinas Inc 's Market Share
|
Morphosys Ag
Share Performance
+96.68%
This Year
|
Morphosys Ag
Profile
Morphosys Ag's business model revolves around the development and commercialization of therapeutic antibodies.
More about Morphosys Ag's Market Share
|
Kiniksa Pharmaceuticals International Plc
Share Performance
+30.79%
30 Days
|
Kiniksa Pharmaceuticals International Plc
Profile
Kiniksa Pharmaceuticals Ltd is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with debilitating diseases and unmet medical needs. Their business model revolves around identifying potential drug candidates, conducting rigorous research and development, and ultimately bringing these drugs to market to provide innovative treatment options. They generate revenue through the sale of their products and collaborations with other companies for the development and commercialization of their therapies.
More about Kiniksa Pharmaceuticals International Plc's Market Share
|
Puma Biotechnology Inc
Share Performance
-19.13%
One Year
|
Puma Biotechnology Inc
Profile
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
More about Puma Biotechnology Inc 's Market Share
|
Kronos Bio Inc
Share Performance
-29.00%
This Year
|
Kronos Bio Inc
Profile
Kronos Bio Inc's business model focuses on developing therapeutics for the treatment of cancer. They utilize a precision medicine approach to target and inhibit novel transcription factors, which play a critical role in the progression of various types of cancer.
More about Kronos Bio Inc 's Market Share
|
Innoviva Inc
Share Performance
+4.92%
This Quarter
|
Innoviva Inc
Profile
Innoviva Inc's business model revolves around the development and commercialization of pharmaceutical products. The company primarily focuses on creating strategic collaborations and partnerships with biopharmaceutical companies to advance innovative therapies. Innoviva generates revenue through royalty payments received based on the sales of its partnered products.
More about Innoviva Inc 's Market Share
|
Atea Pharmaceuticals Inc
Share Performance
-6.15%
This Quarter
|
Atea Pharmaceuticals Inc
Profile
Atea Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing antiviral therapeutics to combat infectious diseases. Their business model revolves around identifying and advancing novel drug candidates that target specific viral mechanisms and inhibit their replication. This includes conducting preclinical and clinical trials, engaging in strategic partnerships, and ultimately bringing effective antiviral treatments to market.
More about Atea Pharmaceuticals Inc 's Market Share
|
Myovant Sciences Ltd
Share Performance
+0.19%
This Year
|
Myovant Sciences Ltd
Profile
Myovant Sciences Ltd operates under a biopharmaceutical business model primarily focused on the development and commercialization of therapies for women's health and prostate cancer. The company aims to leverage its expertise in clinical research, regulatory affairs, and manufacturing to bring innovative treatments to market and improve patients' lives. Myovant Sciences employs a combination of in-house research and development along with collaboration with strategic partners to advance its pipeline of product candidates.
More about Myovant Sciences Ltd 's Market Share
|
Galapagos Nv
Share Performance
+5.35%
One Year
|
Galapagos Nv
Profile
Galapagos Nv's business model is centered around the development and commercialization of innovative medicines. They leverage their expertise in drug discovery and development to collaborate with partners in the healthcare industry, focusing on the advancement of novel therapies to address unmet medical needs.
More about Galapagos Nv's Market Share
|
Mereo Biopharma Group Plc
Share Performance
-11.81%
30 Days
|
Mereo Biopharma Group Plc
Profile
Mereo Biopharma Group Plc's business model focuses on the development and commercialization of innovative therapeutics for rare diseases.
More about Mereo Biopharma Group Plc's Market Share
|
Biora Therapeutics Inc
Share Performance
0.00%
30 Days
|
Biora Therapeutics Inc
Profile
Biora Therapeutics Inc is a biotechnology company that specializes in the development of advanced wound healing therapies. Their business model revolves around researching and designing innovative, tissue-engineered products for various applications in the field of regenerative medicine. They aim to commercialize these products through partnerships with pharmaceutical companies and healthcare providers, ultimately delivering effective and transformative solutions for patients with acute and chronic wounds.
More about Biora Therapeutics Inc 's Market Share
|
Madrigal Pharmaceuticals Inc
Share Performance
-14.73%
This Year
|
Madrigal Pharmaceuticals Inc
Profile
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
More about Madrigal Pharmaceuticals Inc 's Market Share
|
Annovis Bio Inc
Share Performance
-6.60%
Over The Past 5 Days
|
Annovis Bio Inc
Profile
Annovis Bio Inc's business model revolves around developing novel therapeutics to treat neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and ALS (amyotrophic lateral sclerosis). They focus on identifying and targeting multiple disease pathways simultaneously to address the complex nature of these disorders.
More about Annovis Bio Inc 's Market Share
|
Medicinova Inc
Share Performance
-33.80%
This Year
|
Medicinova Inc
Profile
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
More about Medicinova Inc 's Market Share
|
Eyenovia inc
Share Performance
+1,375.00%
This Year
|
Eyenovia inc
Profile
Eyenovia Inc's business model revolves around developing and commercializing innovative ophthalmic products utilizing its proprietary microfluidic ejection technology. The company aims to enhance treatment options for eye diseases and conditions by delivering more precise and targeted ocular therapeutics. Eyenovia focuses on creating user-friendly, high-precision, and cost-effective eye droppers to improve patient compliance and overall treatment outcomes.
More about Eyenovia inc 's Market Share
|
Phathom Pharmaceuticals Inc
Share Performance
-45.16%
This Year
|
Phathom Pharmaceuticals Inc
Profile
Phathom Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing treatments for gastrointestinal diseases. Their business model involves advancing their pipeline of drug candidates through research and development, and seeking regulatory approval for commercialization. By strategically targeting unmet medical needs in the gastrointestinal space, Phathom Pharmaceuticals aims to provide innovative solutions to improve patient outcomes.
More about Phathom Pharmaceuticals Inc 's Market Share
|
Xtl Biopharmaceuticals Ltd
Share Performance
-14.62%
30 Days
|
Xtl Biopharmaceuticals Ltd
Profile
Xtl Biopharmaceuticals Ltd's business model revolves around developing and commercializing innovative biopharmaceutical products.
More about Xtl Biopharmaceuticals Ltd 's Market Share
|
Biovie Inc
Share Performance
-3.74%
Over The Past 5 Days
|
Biovie Inc
Profile
Biovie Inc is a biotechnology company that aims to develop advanced therapeutic solutions for various diseases. They have a unique business model that focuses on research and development of innovative drugs, strategic partnerships and collaborations with other organizations, along with potential commercialization of their products to generate revenue. Their goal is to create groundbreaking medical treatments that improve the quality of life for patients.
More about Biovie Inc 's Market Share
|
Verona Pharma Plc
Share Performance
+10.45%
This Quarter
|
Verona Pharma Plc
Profile
Verona Pharma Plc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for respiratory diseases. Their business model revolves around discovering and advancing new drug candidates, conducting clinical trials, and ultimately bringing these potential treatments to market. By leveraging their expertise in respiratory medicine, they aim to address unmet medical needs and improve the lives of patients suffering from respiratory conditions.
More about Verona Pharma Plc's Market Share
|
Vera Therapeutics Inc
Share Performance
-53.46%
This Year
|
Vera Therapeutics Inc
Profile
Vera Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing innovative therapies for patients with rare and serious diseases. Their business model focuses on researching and developing novel drug candidates, conducting clinical trials, and obtaining regulatory approvals to bring their products to market. By targeting niche patient populations with unmet medical needs, they aim to provide effective treatment options and improve patient outcomes.
More about Vera Therapeutics Inc 's Market Share
|
Astria Therapeutics Inc
Share Performance
-7.98%
Over The Past 5 Days
|
Astria Therapeutics Inc
Profile
Astria Therapeutics Inc's business model centers around developing and commercializing innovative therapeutics for various diseases and medical conditions.
More about Astria Therapeutics Inc 's Market Share
|
Dice Therapeutics Inc
Share Performance
+0.36%
Over The Past 5 Days
|
Dice Therapeutics Inc
Profile
Dice Therapeutics Inc. is a biotechnology company that focuses on developing novel therapies for various diseases. Their business model revolves around leveraging innovative science and technology to identify and target disease drivers, aiming to discover and develop drug candidates that can offer substantial clinical benefits to patients. Through strategic partnerships and collaborations, they aim to bring their therapies to the market efficiently and meet the unmet medical needs in the healthcare industry.
More about Dice Therapeutics Inc 's Market Share
|
Ventyx Biosciences Inc
Share Performance
+4.97%
This Quarter
|
Ventyx Biosciences Inc
Profile
Ventyx Biosciences Inc is a biotechnology company that follows a research and development-focused business model. It aims to develop innovative biopharmaceutical products and therapeutic solutions by leveraging its expertise in various fields such as genetic engineering, drug discovery, and clinical trials. The company seeks to form strategic partnerships and licensing agreements to accelerate the commercialization of its products.
More about Ventyx Biosciences Inc 's Market Share
|
Xilio Therapeutics inc
Share Performance
-4.97%
This Quarter
|
Xilio Therapeutics inc
Profile
Xilio Therapeutics Inc is a biotechnology company focused on developing and commercializing novel immunotherapies to treat cancer.
More about Xilio Therapeutics inc 's Market Share
|
Prelude Therapeutics Inc
Share Performance
-29.10%
This Year
|
Prelude Therapeutics Inc
Profile
Prelude Therapeutics Inc is a biopharmaceutical company that focuses on developing innovative small molecule therapeutic products for cancer treatment. Their business model revolves around conducting extensive research and employing a target discovery engine to identify and validate potential drug targets. By using a combination of proprietary technologies and collaborations with academic institutions, Prelude Therapeutics aims to develop and commercialize novel oncology therapies to address unmet medical needs.
More about Prelude Therapeutics Inc's Market Share
|
Eqrx Inc
Share Performance
+4.93%
30 Days
|
Eqrx Inc
Profile
Eqrx Inc is a pharmaceutical company that focuses on creating affordable and accessible medication. They employ an innovative business model that combines research and development with scientific expertise to develop generic alternatives to the high-priced drugs in the market. By bypassing the traditional pharmaceutical pricing system, Eqrx aims to make essential medications more affordable for patients and healthcare providers.
More about Eqrx Inc 's Market Share
|
Inflarx N v
Share Performance
+4.52%
Over The Past 5 Days
|
Inflarx N v
Profile
Inflarx N is a company that operates on a B2B (business-to-business) model. They offer a range of services and products such as software solutions, data analytics, and consulting to businesses in the technology sector. Their revenue primarily comes from subscription fees, licensing, and consulting fees.
More about Inflarx N v 's Market Share
|
Wave Life Sciences Ltd
Share Performance
-4.34%
One Year
|
Wave Life Sciences Ltd
Profile
Wave Life Sciences Ltd is a biotechnology company focused on developing and commercializing nucleic acid therapies for rare genetic diseases. Their business model revolves around utilizing their proprietary chemistry platform to design and create custom-built, targeted medicines that can potentially address a wide range of genetic disorders. They aim to bring these therapies through preclinical and clinical development stages and ultimately deliver innovative treatments to patients in need.
More about Wave Life Sciences Ltd 's Market Share
|
Therapeuticsmd Inc
Share Performance
+27.19%
30 Days
|
Therapeuticsmd Inc
Profile
TherapeuticsMD Inc is a pharmaceutical company that focuses on developing and commercializing innovative hormone therapy products for women. Their business model revolves around research, development, and marketing of prescription and over-the-counter products catering to women's health needs. By leveraging strategic partnerships and collaborations, they aim to bring their products to market, ultimately improving the quality of life for women.
More about Therapeuticsmd Inc's Market Share
|
Legend Biotech Corporation
Share Performance
-16.76%
This Year
|
Legend Biotech Corporation
Profile
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
More about Legend Biotech Corporation's Market Share
|
Biohaven Ltd
Share Performance
-33.16%
30 Days
|
Biohaven Ltd
Profile
Biohaven Ltd operates as a pharmaceutical company that focuses on discovering and developing therapies for neurological diseases and rare disorders. Their business model revolves around conducting extensive research and clinical trials to bring innovative treatments to market. By collaborating with healthcare professionals, regulatory agencies, and investors, Biohaven aims to improve the lives of patients suffering from these conditions and provide a significant return on investment for stakeholders.
More about Biohaven Ltd 's Market Share
|
Royalty Pharma Plc
Share Performance
+25.82%
This Year
|
Royalty Pharma Plc
Profile
Royalty Pharma Plc operates as a pharmaceutical investment company, focusing on acquiring and managing royalty interests in approved drugs. Their business model primarily revolves around purchasing existing royalty streams in exchange for upfront payments, allowing them to generate ongoing cash flows from the sales of these drugs. They aim to provide liquidity to stakeholders, such as biotech and pharmaceutical companies, by offering a financial alternative to traditional financing options.
More about Royalty Pharma Plc's Market Share
|
Horizon Therapeutics Public Limited Company
Share Performance
+0.81%
30 Days
|
Horizon Therapeutics Public Limited Company
Profile
Horizon Therapeutics Public Limited Company operates as a biopharmaceutical company that develops and commercializes medicines for the treatment of rare diseases. Their business model revolves around acquiring and developing innovative therapies and then distributing them to patients in need. By focusing on rare diseases with high unmet needs, Horizon Therapeutics aims to provide life-changing treatments to underserved patient populations.
More about Horizon Therapeutics Public Limited Company's Market Share
|
Jazz Pharmaceuticals Plc
Share Performance
-12.68%
This Year
|
Jazz Pharmaceuticals Plc
Profile
Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of medical conditions. Their business model revolves around conducting extensive research and development to identify novel molecules and compounds that can address unmet medical needs. By leveraging strategic partnerships, acquisitions, and licensing agreements, they aim to bring these therapies to market and provide valuable treatment options to patients worldwide.
More about Jazz Pharmaceuticals Plc's Market Share
|
Bausch Health Companies Inc
Share Performance
-18.80%
30 Days
|
Bausch Health Companies Inc
Profile
Bausch Health Companies Inc operates through three segments: Bausch + Lomb/International, Salix, and Ortho Dermatologics. The company focuses on developing, manufacturing, and marketing a wide range of pharmaceutical products, medical devices, and over-the-counter products primarily in the areas of eye health, gastroenterology, and dermatology. Bausch Health aims to provide innovative and quality healthcare solutions to improve patients' lives globally.
More about Bausch Health Companies Inc 's Market Share
|
Teva Pharmaceutical Industries Limited
Share Performance
+1.31%
This Quarter
|
Teva Pharmaceutical Industries Limited
Profile
Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company that focuses on the development, production, and marketing of generic and specialty medicines. They aim to provide affordable and accessible healthcare solutions to patients worldwide.
More about Teva Pharmaceutical Industries Limited's Market Share
|
Viatris Inc
Share Performance
-5.37%
Over The Past 5 Days
|
Viatris Inc
Profile
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
More about Viatris Inc 's Market Share
|
Azitra Inc
Share Performance
-22.06%
This Quarter
|
Azitra Inc
Profile
Azitra Inc is a company that operates on a business model focused on developing and commercializing microbiome-based therapeutics for various skin conditions. It aims to use the potential of the human skin microbiome to develop innovative and effective treatments.
More about Azitra Inc 's Market Share
|
Acelyrin Inc
Share Performance
-31.21%
This Year
|
Acelyrin Inc
Profile
Acelyrin Inc is a technology company that focuses on providing cutting-edge solutions in the healthcare industry. Their business model is centered around developing innovative software and hardware products that improve patient outcomes, enhance operational efficiency, and drive cost savings for healthcare organizations. By offering a range of advanced tools and services, Acelyrin Inc aims to revolutionize the healthcare sector and contribute to the overall advancement of digital health.
More about Acelyrin Inc 's Market Share
|
Dianthus Therapeutics Inc
Share Performance
-4.39%
Over The Past 5 Days
|
Dianthus Therapeutics Inc
Profile
Dianthus Therapeutics Inc is a biotechnology company that focuses on developing novel genetic medicines for patients suffering from rare genetic diseases. Their business model revolves around leveraging cutting-edge gene therapy technologies to design and deliver innovative treatments. By partnering with academic institutions and utilizing a proprietary gene therapy platform, they aim to address unmet medical needs and provide potential new therapies for patients with genetic disorders.
More about Dianthus Therapeutics Inc 's Market Share
|
Medicure Inc
Share Performance
0.00%
This Year
|
Medicure Inc
Profile
Medicure Inc operates as a pharmaceutical company with a business model that focuses on the research, development, and commercialization of innovative cardiovascular and other specialty pharmaceuticals. They aim to address unmet medical needs, improve patient outcomes, and deliver value to healthcare providers and consumers.
More about Medicure Inc 's Market Share
|
Nexien Biopharma Inc
Share Performance
0.00%
This Year
|
Nexien Biopharma Inc
Profile
Nexien Biopharma Inc operates as a biotechnology company focused on the development and commercialization of innovative therapies for various medical conditions. They aim to use their expertise in biopharmaceutical research to bring novel treatments to market, improving patient outcomes and meeting unmet medical needs.
More about Nexien Biopharma Inc 's Market Share
|
Protokinetix Incorporated
Share Performance
-14.00%
30 Days
|
Protokinetix Incorporated
Profile
Protokinetix Incorporated's business model revolves around the commercialization of its proprietary technology, AAGP? (Antifreeze Protein Analog).
More about Protokinetix Incorporated's Market Share
|
Aptinyx Inc
Share Performance
+1.05%
Over The Past 5 Days
|
Aptinyx Inc
Profile
Aptinyx Inc's business model involves developing and commercializing novel therapies for brain and nervous system disorders. They focus on utilizing their proprietary chemistry platform to discover and develop small molecule therapies that target specific receptors, with an aim to address the unmet medical needs in central nervous system disorders.
More about Aptinyx Inc 's Market Share
|
Aravive Inc
Share Performance
-17.32%
Over The Past 5 Days
|
Aravive Inc
Profile
Aravive Inc operates on a business model that focuses on developing and commercializing innovative therapies to treat life-threatening diseases by targeting key signaling pathways.
More about Aravive Inc 's Market Share
|
Nascent Biotech Inc
Share Performance
0.00%
One Year
|
Nascent Biotech Inc
Profile
Nascent Biotech Inc's business model is focused on the development and commercialization of innovative therapies in the field of biotechnology. They aim to leverage their expertise and research to bring new drugs to market that can address critical unmet medical needs.
More about Nascent Biotech Inc 's Market Share
|
Aptevo Therapeutics Inc
Share Performance
-60.18%
30 Days
|
Aptevo Therapeutics Inc
Profile
Aptevo Therapeutics Inc operates as a biotechnology company that focuses on the development of novel oncology and hematology therapeutics. The company primarily generates revenue through the sale of its products and potential collaborations with other pharmaceutical companies.
More about Aptevo Therapeutics Inc 's Market Share
|
Blue Water Vaccines Inc
Share Performance
-83.16%
One Year
|
Blue Water Vaccines Inc
Profile
Blue Water Biotech Inc's business model involves leveraging biotechnology to develop and offer innovative solutions for various industries.
More about Blue Water Vaccines Inc's Market Share
|
Applied Molecular Transport Inc
Share Performance
+50.46%
This Quarter
|
Applied Molecular Transport Inc
Profile
Applied Molecular Transport Inc (AMT) is a biopharmaceutical company focused on developing and commercializing transformative oral biologic therapeutics. The company utilizes its proprietary drug delivery technology platform to transport biologic drugs across the gastrointestinal tract and deliver them to target tissues. AMT's business model involves partnering with pharmaceutical companies to license its technology and collaborate on the development, manufacturing, and commercialization of oral biologic therapeutics.
More about Applied Molecular Transport Inc 's Market Share
|
Nucana Plc
Share Performance
-96.51%
This Quarter
|
Nucana Plc
Profile
Nucana Plc is a pharmaceutical company that focuses on developing novel treatments for cancer and other diseases.
More about Nucana Plc's Market Share
|
Timber Pharmaceuticals Inc
Share Performance
-17.80%
Over The Past 5 Days
|
Timber Pharmaceuticals Inc
Profile
Timber Pharmaceuticals Inc is a pharmaceutical company that operates on a business model centered around the research and development of innovative therapeutics. They focus on identifying and advancing novel treatments for various dermatological conditions. By leveraging their expertise in drug development, Timber Pharmaceuticals aims to bring safe and effective medications to market to address the unmet needs in dermatology.
More about Timber Pharmaceuticals Inc 's Market Share
|
Apexigen Inc
Share Performance
-10.44%
30 Days
|
Apexigen Inc
Profile
Apexigen Inc's business model revolves around developing and commercializing novel antibody-based therapeutics. They focus on discovering and optimizing antibody drugs through their proprietary technology platforms. By partnering with pharmaceutical companies or utilizing their own resources, they aim to provide innovative solutions for treating various diseases and improving patients' lives.
More about Apexigen Inc 's Market Share
|
Allarity Therapeutics Inc
Share Performance
-94.04%
One Year
|
Allarity Therapeutics Inc
Profile
Allarity Therapeutics Inc is a biotechnology company that leverages its unique drug response profiling platform to develop personalized cancer treatments. They use AI algorithms to match patients with the most effective therapies by analyzing their individual molecular profiles.
More about Allarity Therapeutics Inc 's Market Share
|
Viracta Therapeutics Inc
Share Performance
-89.88%
This Year
|
Viracta Therapeutics Inc
Profile
Viracta Therapeutics Inc is a biopharmaceutical company focused on developing targeted therapies for viral-associated cancers. The company aims to advance research, develop innovative treatments, and commercialize products to improve the lives of patients suffering from these types of cancers.
More about Viracta Therapeutics Inc 's Market Share
|
Biophytis Sa
Share Performance
-25.59%
Over The Past 5 Days
|
Biophytis Sa
Profile
Biophytis SA is a biotechnology company that focuses on developing innovative therapeutics for age-related diseases, with a specific emphasis on degenerative eye diseases and muscle wasting conditions. They leverage their expertise in biology and clinical development to discover and advance targeted drug candidates, aiming to address the unmet medical needs of patients in these areas.
More about Biophytis Sa's Market Share
|
Paxmedica Inc
Share Performance
0.00%
Over The Past 5 Days
|
Paxmedica Inc
Profile
Paxmedica Inc's business model revolves around providing innovative solutions and technologies in the healthcare sector.
More about Paxmedica Inc 's Market Share
|
Neubase Therapeutics inc
Share Performance
+83.50%
One Year
|
Neubase Therapeutics inc
Profile
Neubase Therapeutics Inc is a biotechnology company focused on developing and commercializing small molecule therapies for genetic diseases. They aim to leverage their proprietary modular antisense oligonucleotide platform to create therapeutics that can specifically target and treat multiple genetic diseases.
More about Neubase Therapeutics inc 's Market Share
|
Galecto Inc
Share Performance
-81.01%
One Year
|
Galecto Inc
Profile
Galecto Inc operates on a business model that focuses on developing novel therapeutics based on galectin inhibitors, targeting fibrosis and inflammation-related diseases. The company aims to bring these innovative drugs to market by leveraging their expertise in drug discovery and development, while forming strategic partnerships and collaborations within the pharmaceutical industry.
More about Galecto Inc 's Market Share
|
Protagenic Therapeutics Inc new
Share Performance
+816.27%
This Year
|
Protagenic Therapeutics Inc new
Profile
Protagenic Therapeutics Inc has developed a novel business model focused on the discovery and development of novel therapeutics targeting the PGRMC1 receptor, which plays a crucial role in various diseases. By leveraging their proprietary technology and partnerships, the company aims to advance the development of innovative drugs that can effectively treat a range of conditions influenced by the PGRMC1 receptor.
More about Protagenic Therapeutics Inc new's Market Share
|
Lipella Pharmaceuticals Inc
Share Performance
+12.40%
30 Days
|
Lipella Pharmaceuticals Inc
Profile
: { message: That model is currently overloaded with other requests. You can retry your request, or contact us through our help center at help.openai.com if the error persists. (Pleas
More about Lipella Pharmaceuticals Inc 's Market Share
|
Nanoviricides inc
Share Performance
-19.73%
One Year
|
Nanoviricides inc
Profile
Nanoviricides Inc. is a pharmaceutical company that operates on a business model based on the development and commercialization of nanomedicines.
More about Nanoviricides inc 's Market Share
|
Connect Biopharma Holdings Limited
Share Performance
-2.39%
30 Days
|
Connect Biopharma Holdings Limited
Profile
Connect Biopharma Holdings Limited is a biotechnology company that develops novel therapies for inflammatory diseases by targeting the immune system. Their business model includes research and development of innovative drugs, clinical trials, and partnerships with pharmaceutical companies for commercialization.
More about Connect Biopharma Holdings Limited's Market Share
|
Hoth Therapeutics Inc
Share Performance
-0.55%
30 Days
|
Hoth Therapeutics Inc
Profile
Hoth Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for dermatological disorders and other related conditions.
More about Hoth Therapeutics Inc's Market Share
|
Adial Pharmaceuticals Inc
Share Performance
-44.82%
One Year
|
Adial Pharmaceuticals Inc
Profile
Adial Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing medications for the treatment of alcohol use disorder. Their business model revolves around conducting clinical trials, obtaining regulatory approvals, and marketing their products to healthcare professionals and potential patients.
More about Adial Pharmaceuticals Inc's Market Share
|
Immuron Limited
Share Performance
-0.53%
This Quarter
|
Immuron Limited
Profile
Immuron Limited's business model involves the development and commercialization of oral immunotherapeutics that target and treat various diseases.
More about Immuron Limited's Market Share
|
Aquestive Therapeutics Inc
Share Performance
-21.93%
This Quarter
|
Aquestive Therapeutics Inc
Profile
Aquestive Therapeutics Inc follows a business model that focuses on the development and commercialization of innovative products to address unmet medical needs. The company primarily operates in the pharmaceutical industry, leveraging its proprietary drug delivery technology to create and improve various medications for patients.
More about Aquestive Therapeutics Inc 's Market Share
|
Esperion Therapeutics Inc
Share Performance
-8.52%
Over The Past 5 Days
|
Esperion Therapeutics Inc
Profile
Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.
More about Esperion Therapeutics Inc 's Market Share
|
Calcimedica Inc
Share Performance
-45.29%
This Year
|
Calcimedica Inc
Profile
Calcimedica Inc is a biopharmaceutical company that focuses on the research and development of small molecule drugs to treat a range of diseases caused by calcium dysregulation. Their business model involves identifying potential drug candidates, conducting preclinical and clinical trials, and eventually commercializing these drugs to address unmet medical needs.
More about Calcimedica Inc 's Market Share
|
Cellectar Biosciences Inc
Share Performance
-2.50%
Over The Past 5 Days
|
Cellectar Biosciences Inc
Profile
Cellectar Biosciences Inc is a biopharmaceutical company that focuses on the development of targeted cancer therapies. They utilize their proprietary drug conjugation platform to create targeted small molecules that can selectively bind and deliver radioactive isotopes directly to cancer cells. Their business model revolves around developing and commercializing these innovative therapies for the treatment of various types of cancer, aiming to improve patient outcomes and potentially revolutionize cancer treatment.
More about Cellectar Biosciences Inc 's Market Share
|
Alimera Sciences Inc
Share Performance
+63.42%
One Year
|
Alimera Sciences Inc
Profile
Alimera Sciences Inc operates under a business model focused on research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company primarily specializes in creating products for the treatment of retinal diseases, such as diabetic macular edema (DME), utilizing their proprietary sustained-release delivery technology. These products are designed to provide long-term treatment options for patients, offering potential benefits such as less frequent injections and improved patient compliance.
More about Alimera Sciences Inc's Market Share
|
Edesa Biotech Inc
Share Performance
-19.34%
This Quarter
|
Edesa Biotech Inc
Profile
Edesa Biotech Inc's business model focuses on the development and commercialization of innovative therapeutics in the field of dermatology and gastrointestinal diseases.
More about Edesa Biotech Inc 's Market Share
|
Journey Medical Corp
Share Performance
+34.87%
This Quarter
|
Journey Medical Corp
Profile
Journey Medical Corporation is a pharmaceutical and medical device company that specializes in developing and commercializing innovative products for dermatology and aesthetics. Their business model revolves around conducting research and development to create new products, acquiring the necessary regulatory approvals, and partnering with healthcare professionals to effectively distribute and market these products. By focusing on dermatology and aesthetics, Journey Medical Corporation aims to address unmet medical needs and provide cutting-edge solutions to improve patient outcomes in these fields.
More about Journey Medical Corp's Market Share
|
Vistagen Therapeutics Inc
Share Performance
-27.41%
This Year
|
Vistagen Therapeutics Inc
Profile
Vistagen Therapeutics Inc is a pharmaceutical company that specializes in developing and commercializing innovative therapies for mental health disorders. Their business model focuses on advanced research and development of novel drug candidates targeting major depressive disorder, social anxiety disorder, and other mental health conditions. By partnering with strategic collaborators and utilizing their proprietary technologies, Vistagen aims to bring effective treatments to patients and address the unmet needs in the mental health sector.
More about Vistagen Therapeutics Inc 's Market Share
|
Mineralys Therapeutics Inc
Share Performance
+30.82%
One Year
|
Mineralys Therapeutics Inc
Profile
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
More about Mineralys Therapeutics Inc 's Market Share
|
Genelux Corporation
Share Performance
+7.05%
This Year
|
Genelux Corporation
Profile
Genelux Corporation's business model revolves around the development and commercialization of innovative genetic-based therapies and technologies.
More about Genelux Corporation's Market Share
|
Pliant Therapeutics Inc
Share Performance
-58.12%
This Quarter
|
Pliant Therapeutics Inc
Profile
Pliant Therapeutics Inc operates with a business model focused on developing novel therapeutics to address fibrotic diseases. The company conducts extensive research to identify and target specific molecular pathways involved in fibrosis, with the aim of developing effective treatments. Pliant Therapeutics collaborates with academic institutions and conducts preclinical and clinical studies to bring its products to market and improve the lives of patients suffering from fibrotic conditions.
More about Pliant Therapeutics Inc 's Market Share
|
Bicycle Therapeutics Plc
Share Performance
-6.72%
Over The Past 5 Days
|
Bicycle Therapeutics Plc
Profile
Bicycle Therapeutics Plc's business model is centered around the development and commercialization of novel therapeutics using its proprietary bicyclic peptide platform.
More about Bicycle Therapeutics Plc's Market Share
|
Agios Pharmaceuticals Inc
Share Performance
-5.40%
One Year
|
Agios Pharmaceuticals Inc
Profile
Agios Pharmaceuticals Inc is a biopharmaceutical company that focuses on researching and developing innovative therapies for treating genetic diseases and cancer.
More about Agios Pharmaceuticals Inc 's Market Share
|
Mirum Pharmaceuticals Inc
Share Performance
+4.66%
This Year
|
Mirum Pharmaceuticals Inc
Profile
Mirum Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing innovative therapies for patients with rare liver diseases.
More about Mirum Pharmaceuticals Inc 's Market Share
|
Puretech Health Plc
Share Performance
-6.57%
This Year
|
Puretech Health Plc
Profile
Puretech Health Plc is a biotechnology company that operates a unique business model focusing on innovation and entrepreneurship. They identify and validate disruptive technologies and build and invest in companies around those technologies, with a focus on identifying unmet medical needs. By developing a diversified portfolio of cutting-edge healthcare companies, Puretech aims to deliver breakthrough therapies to improve patient outcomes.
More about Puretech Health Plc's Market Share
|
Mirati Therapeutics Inc
Share Performance
-0.14%
30 Days
|
Mirati Therapeutics Inc
Profile
Mirati Therapeutics Inc is a biotechnology company that focuses on the research, discovery, and development of precision oncology treatments for patients with cancer. Their business model involves leveraging their proprietary drug discovery platform to identify and develop targeted therapies, and collaborating with partners for the commercialization of their products.
More about Mirati Therapeutics Inc 's Market Share
|
Abbvie Inc
Share Performance
+16.68%
One Year
|
Abbvie Inc
Profile
AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.
More about Abbvie Inc 's Market Share
|
Infinity Pharmaceuticals Inc
Share Performance
-96.19%
This Quarter
|
Infinity Pharmaceuticals Inc
Profile
Infinity Pharmaceuticals Inc's business model revolves around the discovery, development, and commercialization of innovative therapies for the treatment of challenging diseases, primarily in the field of oncology.
More about Infinity Pharmaceuticals Inc 's Market Share
|
Q Biomed inc
Share Performance
0.00%
This Year
|
Q Biomed inc
Profile
Q Biomed Inc's business model revolves around identifying and acquiring biomedical assets with potential for significant commercial success. They aim to develop these assets through strategic partnerships and collaborations, ultimately bringing innovative products and treatments to market.
More about Q Biomed inc 's Market Share
|
Werewolf Therapeutics Inc
Share Performance
+28.19%
30 Days
|
Werewolf Therapeutics Inc
Profile
Werewolf Therapeutics Inc operates with a business model focused on utilizing innovative technologies to develop therapies targeting cancer using immune cell activation.
More about Werewolf Therapeutics Inc 's Market Share
|
Sources: Zymeworks Inc and all companies mentioned above in this report
|
